UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 27, 2008
or
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-33301
ACCURAY INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
|
20-8370041 |
1310 Chesapeake Terrace
Sunnyvale, California 94089
(Address of Principal Executive Offices Including Zip Code)
(408) 716-4600
(Registrants Telephone Number, Including Area Code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o |
|
Accelerated filer x |
|
|
|
Non-accelerated filer o |
|
Smaller reporting company o |
(Do not check if a smaller reporting company) |
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No
As of January 30, 2009, there were 55,636,699 shares of the Registrants Common Stock, par value $0.001 per share, outstanding.
Accuray Incorporated
Form 10-Q for the Quarter Ended December 31, 2008
|
|
Page No. |
3 |
||
|
|
|
3 |
||
|
3 |
|
|
4 |
|
|
5 |
|
|
6 |
|
|
|
|
Managements Discussion and Analysis of Financial Condition and Results of Operations |
22 |
|
|
|
|
35 |
||
|
|
|
36 |
||
|
|
|
37 |
||
|
|
|
37 |
||
|
|
|
37 |
||
|
|
|
40 |
||
|
|
|
40 |
||
|
|
|
40 |
||
|
|
|
41 |
||
|
|
|
41 |
||
|
|
|
42 |
||
|
|
|
43 |
2
Accuray Incorporated
Condensed Consolidated Balance Sheets
(in thousands, except share amounts)
(unaudited)
|
|
December 31, |
|
June 30, |
|
||
|
|
2008 |
|
2008 |
|
||
Assets |
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
29,373 |
|
$ |
36,936 |
|
Restricted cash |
|
581 |
|
4,830 |
|
||
Short-term available-for-sale securities |
|
80,242 |
|
85,536 |
|
||
Accounts receivable, net of allowance for doubtful accounts of $195 at December 31, 2008 and $27 at June 30, 2008 |
|
40,935 |
|
33,918 |
|
||
Inventories |
|
24,080 |
|
23,047 |
|
||
Prepaid expenses and other current assets |
|
8,824 |
|
6,431 |
|
||
Deferred cost of revenuecurrent |
|
21,968 |
|
31,667 |
|
||
Total current assets |
|
206,003 |
|
222,365 |
|
||
Long-term available-for-sale securities |
|
22,947 |
|
37,014 |
|
||
Long-term trading securities |
|
21,540 |
|
|
|
||
Deferred cost of revenuenoncurrent |
|
12,209 |
|
11,724 |
|
||
Property and equipment, net |
|
16,158 |
|
17,140 |
|
||
Goodwill |
|
4,495 |
|
4,495 |
|
||
Intangible assets, net |
|
797 |
|
926 |
|
||
Other assets |
|
1,402 |
|
1,340 |
|
||
Total assets |
|
$ |
285,551 |
|
$ |
295,004 |
|
Liabilities and stockholders equity |
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
||
Accounts payable |
|
$ |
9,329 |
|
$ |
12,962 |
|
Accrued compensation |
|
10,256 |
|
7,504 |
|
||
Other accrued liabilities |
|
6,457 |
|
4,369 |
|
||
Customer advancescurrent |
|
17,408 |
|
22,331 |
|
||
Deferred revenuecurrent |
|
69,453 |
|
87,455 |
|
||
Total current liabilities |
|
112,903 |
|
134,621 |
|
||
Long-term liabilities: |
|
|
|
|
|
||
Customer advancesnoncurrent |
|
1,500 |
|
2,900 |
|
||
Deferred revenuenoncurrent |
|
28,538 |
|
26,720 |
|
||
Total liabilities |
|
142,941 |
|
164,241 |
|
||
Commitments and contingencies (Note 7) |
|
|
|
|
|
||
Stockholders equity |
|
|
|
|
|
||
Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issued and outstanding |
|
|
|
|
|
||
Common stock, $0.001 par value; authorized: 100,000,000 shares; issued: 57,697,449 and 56,719,864 shares at December 31, 2008 and June 30, 2008, respectively; outstanding: 55,557,431 and 54,579,846 shares at December 31, 2008 and June 30, 2008, respectively |
|
56 |
|
55 |
|
||
Additional paid-in capital |
|
264,970 |
|
252,901 |
|
||
Accumulated other comprehensive income (loss) |
|
539 |
|
(1,067 |
) |
||
Accumulated deficit |
|
(122,955 |
) |
(121,126 |
) |
||
Total stockholders equity |
|
142,610 |
|
130,763 |
|
||
Total liabilities and stockholders equity |
|
$ |
285,551 |
|
$ |
295,004 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Accuray Incorporated
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
|
|
Three Months Ended |
|
Six Months Ended |
|
||||||||
|
|
December 31, |
|
December 31, |
|
||||||||
|
|
2008 |
|
2007 |
|
2008 |
|
2007 |
|
||||
Net revenue: |
|
|
|
|
|
|
|
|
|
||||
Products |
|
$ |
41,301 |
|
$ |
39,131 |
|
$ |
78,756 |
|
$ |
76,115 |
|
Shared ownership program |
|
876 |
|
3,044 |
|
1,912 |
|
5,356 |
|
||||
Services |
|
13,922 |
|
8,950 |
|
29,829 |
|
15,949 |
|
||||
Other |
|
1,538 |
|
913 |
|
2,997 |
|
3,264 |
|
||||
Total net revenue |
|
57,637 |
|
52,038 |
|
113,494 |
|
100,684 |
|
||||
Cost of revenue: |
|
|
|
|
|
|
|
|
|
||||
Cost of products |
|
17,520 |
|
16,481 |
|
32,264 |
|
32,921 |
|
||||
Cost of shared ownership program |
|
207 |
|
760 |
|
469 |
|
1,472 |
|
||||
Cost of services |
|
8,972 |
|
6,391 |
|
20,157 |
|
10,849 |
|
||||
Cost of other |
|
1,529 |
|
544 |
|
2,766 |
|
1,669 |
|
||||
Total cost of revenue |
|
28,228 |
|
24,176 |
|
55,656 |
|
46,911 |
|
||||
Gross profit |
|
29,409 |
|
27,862 |
|
57,838 |
|
53,773 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||
Selling and marketing |
|
10,723 |
|
11,167 |
|
24,203 |
|
21,323 |
|
||||
Research and development |
|
8,794 |
|
8,128 |
|
17,548 |
|
15,843 |
|
||||
General and administrative |
|
9,259 |
|
7,976 |
|
19,692 |
|
15,877 |
|
||||
Total operating expenses |
|
28,776 |
|
27,271 |
|
61,443 |
|
53,043 |
|
||||
Income (loss) from operations |
|
633 |
|
591 |
|
(3,605 |
) |
730 |
|
||||
Other income, net |
|
748 |
|
2,197 |
|
1,861 |
|
4,809 |
|
||||
Income (loss) before provision for income taxes |
|
1,381 |
|
2,788 |
|
(1,744 |
) |
5,539 |
|
||||
Provision for income taxes |
|
31 |
|
445 |
|
85 |
|
931 |
|
||||
Net income (loss) |
|
$ |
1,350 |
|
$ |
2,343 |
|
$ |
(1,829 |
) |
$ |
4,608 |
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
|
||||
Basic net income (loss) per share |
|
$ |
0.02 |
|
$ |
0.04 |
|
$ |
(0.03 |
) |
$ |
0.08 |
|
Shares used in computing basic net earnings per share |
|
55,064 |
|
54,737 |
|
54,845 |
|
54,380 |
|
||||
Diluted net income (loss) per share |
|
$ |
0.02 |
|
$ |
0.04 |
|
$ |
(0.03 |
) |
$ |
0.08 |
|
Shares used in computing diluted net earnings per share |
|
58,267 |
|
61,293 |
|
54,845 |
|
61,257 |
|
||||
Cost of revenue, selling and marketing, research and development, and general and administrative expenses include stock-based compensation charges as follows: |
|
|
|
|
|
|
|
|
|
||||
Cost of revenue |
|
$ |
547 |
|
$ |
530 |
|
$ |
1,179 |
|
$ |
851 |
|
Selling and marketing |
|
$ |
935 |
|
$ |
1,039 |
|
$ |
1,980 |
|
$ |
2,146 |
|
Research and development |
|
$ |
751 |
|
$ |
803 |
|
$ |
1,533 |
|
$ |
1,478 |
|
General and administrative |
|
$ |
1,348 |
|
$ |
1,911 |
|
$ |
3,860 |
|
$ |
4,112 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
Accuray Incorporated
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
|
|
Six Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
Cash Flows From Operating Activities |
|
|
|
|
|
||
Net income (loss) |
|
$ |
(1,829 |
) |
$ |
4,608 |
|
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
|
|
|
|
|
||
Depreciation and amortization |
|
3,304 |
|
3,903 |
|
||
Stock-based compensation |
|
8,552 |
|
8,587 |
|
||
Realized gain on investments |
|
(3 |
) |
|
|
||
Unrealized loss on long-term trading securities, net of gain on put option |
|
860 |
|
|
|
||
Provision for bad debts |
|
168 |
|
|
|
||
Loss on write-down of inventories |
|
1,478 |
|
395 |
|
||
Loss on disposal of property and equipment |
|
66 |
|
6 |
|
||
Changes in assets and liabilities: |
|
|
|
|
|
||
Accounts receivable |
|
(7,467 |
) |
(5,106 |
) |
||
Inventories |
|
(3,340 |
) |
(2,088 |
) |
||
Prepaid expenses and other current assets |
|
(2,204 |
) |
1,014 |
|
||
Deferred cost of revenue |
|
9,199 |
|
9,868 |
|
||
Other assets |
|
(45 |
) |
147 |
|
||
Accounts payable |
|
(3,757 |
) |
(5,124 |
) |
||
Accrued liabilities |
|
5,233 |
|
(4,146 |
) |
||
Customer advances |
|
(6,524 |
) |
2,577 |
|
||
Deferred revenue |
|
(16,387 |
) |
(29,886 |
) |
||
Net cash used in operating activities |
|
(12,696 |
) |
(15,245 |
) |
||
Cash Flows From Investing Activities |
|
|
|
|
|
||
Purchases of property and equipment |
|
(1,415 |
) |
(3,726 |
) |
||
Restricted cash |
|
4,249 |
|
|
|
||
Purchase of marketable securities |
|
(76,079 |
) |
|
|
||
Sale and maturity of marketable securities |
|
74,656 |
|
|
|
||
Net cash provided by (used in) investing activities |
|
1,411 |
|
(3,726 |
) |
||
Cash Flows From Financing Activities |
|
|
|
|
|
||
Proceeds from issuance of common stock |
|
2,698 |
|
2,456 |
|
||
Proceeds from employee stock purchase plan |
|
806 |
|
1,888 |
|
||
Stock repurchases |
|
|
|
(3,341 |
) |
||
Income tax benefits from employee stock plans |
|
|
|
718 |
|
||
Net cash provided by financing activities |
|
3,504 |
|
1,721 |
|
||
Effect of exchange rate changes on cash |
|
218 |
|
(98 |
) |
||
Net decrease in cash and cash equivalents |
|
(7,563 |
) |
(17,348 |
) |
||
Cash and cash equivalents at beginning of period |
|
36,936 |
|
204,830 |
|
||
Cash and cash equivalents at end of period |
|
$ |
29,373 |
|
$ |
187,482 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Accuray Incorporated
Notes to Condensed Consolidated Financial Statements
(unaudited)
1. DESCRIPTION OF BUSINESS
Organization
Accuray Incorporated (the Company) was incorporated in California in December 1990 and commenced operations in January 1992. The Company was reincorporated in Delaware in February 2007 prior to the completion of its initial public offering (IPO). The Company designs, develops and sells the CyberKnife system, an image-guided robotic radiosurgery system used for the treatment of solid tumors anywhere in the body.
The Company has formed ten wholly-owned subsidiaries: Accuray International SARL, located in Geneva, Switzerland, Accuray Europe SARL, located in Paris, France, Accuray UK Ltd, located in London, United Kingdom, Accuray Asia Limited, located in Hong Kong, SAR, Japan Accuray KK, located in Tokyo, Japan, Accuray Spain, S.L.U., located in Madrid, Spain, Accuray Medical Equipment (India) Private Ltd., located in New Delhi, India, Accuray Medical Equipment (SEA) Private Limited, located in Singapore, Accuray Medical Equipment (Rus) LLC, located in Moscow, Russia and Accuray Medical Equipment GmbH, located in Munich, Germany. The purpose of these subsidiaries is to market the Companys products in the various countries in which they are located.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Fiscal Year
The Companys fiscal year ends on the Saturday closest to June 30th, so that in a 52 week period, each fiscal quarter consists of 13 weeks. The additional week in a 53-week year is added to the fourth quarter, making such quarter consist of 14 weeks. Fiscal years 2009 and 2008 are both comprised of 52 weeks. For ease of presentation purposes, the condensed financial statements and notes refer to December 31 as the Companys fiscal quarter end and June 30 as the Companys fiscal year end.
Basis of Presentation and Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. Certain prior period balances have been reclassified to conform to current period presentation.
The accompanying condensed consolidated balance sheet as of December 31, 2008, the condensed consolidated statements of operations for the three and six months ended December 31, 2008 and 2007, and the condensed consolidated statements of cash flows for the six months ended December 31, 2008 and 2007 and other information disclosed in the related notes are unaudited. The condensed consolidated balance sheet as of June 30, 2008 was derived from the Companys audited consolidated financial statements at that date. The accompanying condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Companys Annual Report on Form 10-K for the year ended June 30, 2008.
The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, (U.S. GAAP), pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state the Companys consolidated financial position as of December 31, 2008, consolidated results of operations for the three and six months ended December 31, 2008 and 2007 and cash flows for the six months ended December 31, 2008 and 2007. The results for the three and six months ended December 31, 2008 are not necessarily indicative of the results to be expected for the year ending June 30, 2009 or for any other interim period or for any future year.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Significant estimates and assumptions made by the Company relate to stock-based compensation, valuation allowances for deferred tax assets, estimate of allowance for doubtful accounts, valuation of excess and obsolete inventories, impairment of long-lived assets and goodwill, deferred revenue and deferred cost of revenue. Actual results could differ from those estimates.
Foreign Currency
The Companys international subsidiaries use their local currencies as their functional currencies. For those subsidiaries, assets and liabilities are translated at exchange rates in effect at the balance sheet date and income and expense accounts at average
6
exchange rates during the year. Resulting translation adjustments are recorded directly to accumulated comprehensive income within the statement of stockholders equity. Foreign currency transaction gains and losses are included as a component of other income (expense).
Cash and Cash Equivalents
The Company considers all investments with original maturities of three months or less to be cash equivalents. Cash equivalents amounted to $21.9 million and $30.7 million at December 31, 2008 and June 30, 2008, respectively. Cash and cash equivalent balances denominated in a foreign currency amounted to $1.7 million and $1.0 million at December 31, 2008 and June 30, 2008, respectively.
Marketable Securities
The Companys short-term available-for-sale securities on the condensed consolidated balance sheet include fixed-income securities, commercial paper, term notes and marketable debt securities. All marketable securities designated as available-for-sale are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). Realized gains and losses on the sale of available-for-sale marketable securities are recorded in other income (expense). The cost of available-for-sale marketable securities sold is based on the specific identification method. Available-for-sale marketable securities with original maturities greater than approximately three months and remaining maturities less than one year are classified as short-term available-for-sale marketable securities. Long-term available-for-sale marketable securities include U.S. corporate debt securities with maturities beyond one year.
The Companys long-term trading securities on the condensed consolidated balance sheet and consist of (i) auction-rate securities, or ARS that are AAA-rated and are secured by pools of student loans guaranteed by state regulated higher education agencies and reinsured by the U.S. Department of Education that are designated as trading marketable securities, and (ii) a put option held in respect of these ARS rights (see Note 3). Changes in the fair value of the Companys trading securities are reported in other income (expense).
Fair Value of Financial Instruments
The carrying values of the Companys financial instruments including cash and cash equivalents, restricted cash, short-term marketable securities, accounts receivable and accounts payable are approximately equal to their respective fair values due to the relatively short-term nature of these instruments.
Concentration of Credit Risk and Other Risks and Uncertainties
The Companys cash, cash equivalents and marketable securities are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. These financial instruments are placed with a number of financial institutions, which limits the credit exposure from any one financial institution or instrument.
Accounts receivable are not collateralized. The Company performs ongoing credit evaluations of its customers and maintains reserves for potential credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Accounts are charged against the allowance for doubtful accounts once collection efforts are unsuccessful. Historically, such losses have been within managements expectations. The Companys allowance for doubtful accounts was approximately $195,000 and $27,000 as of December 31, 2008 and June 30, 2008, respectively. There were no customers that represented more than 10% of revenue for the three and six months ended December 31, 2008. For the three and six months ended December 31, 2007, the Company had one customer that represented approximately 18% and 17% of revenue, respectively. At December 31, 2008 and June 30, 2008, the Company had two and three customers that represented approximately 42% and 44% of accounts receivable, respectively.
The Company is subject to risks common to companies in the medical device industry including, but not limited to: new technological innovations, dependence on key personnel, dependence on key suppliers, protection of proprietary technology, compliance with government regulations, uncertainty of widespread market acceptance of products, product liability and the need to obtain additional financing. The Companys products include components subject to rapid technological change. Certain components used in manufacturing have relatively few alternative sources of supply, and establishing additional or replacement suppliers for such components cannot be accomplished quickly. While the Company has ongoing programs to minimize the adverse effect of such uncertainty and considers technological change in estimating its allowances, uncertainty continues to exist.
The products currently under development by the Company may require clearance by the U.S. Food and Drug Administration, or FDA, or other international regulatory agencies prior to commercial sales. There can be no assurance that the Companys products will receive the necessary clearance. If the Company is denied such clearance or such clearance is delayed, such delays or denials could have a material adverse impact on the Company.
7
Revenue Recognition
The Company earns revenue from the sale of products, the operation of its shared ownership program, and the provision of related services, which include installation services, post-contract customer support (PCS), training and consulting. The Companys products and upgrades to those products include software that is essential to the functionality of the products and accordingly, the Company accounts for the sale of its products pursuant to Statement of Position (SOP) No. 97-2, Software Revenue Recognition (SOP 97-2), as amended.
The Company recognizes product revenues for sales of the CyberKnife system, upgrades, components and replacement parts and accessories when there is persuasive evidence of an arrangement, the fee is fixed or determinable, collection of the fee is probable and delivery has occurred as prescribed by SOP 97-2. Payments received in advance of product shipment are recorded as customer advances and are recognized as revenue or deferred revenue upon product shipment or installation.
For arrangements with multiple elements, the Company allocates arrangement consideration to each element based upon vendor specific objective evidence (VSOE) of fair value of the respective elements. VSOE of fair value for each element is based upon the Companys standard rates charged for the product or service when such product or service is sold separately or based upon the price established by management having the relevant authority when that product or service is not yet being sold separately. When contracts contain multiple elements, and VSOE of fair value exists for all undelivered elements, the Company accounts for the delivered elements, principally the CyberKnife system, based upon the residual method as prescribed by SOP No. 98-9, Modification of SOP No. 97-2 with Respect to Certain Transactions (SOP 98-9). If VSOE of fair value does not exist for all the undelivered elements, all revenue is deferred until the earlier of: (1) delivery of all elements, or (2) establishment of VSOE of fair value for all remaining undelivered elements.
CyberKnife sales with legacy service plans
For sales of CyberKnife systems with PCS arrangements that include specified or committed upgrades for which the Company has not established VSOE of fair value, all revenue is deferred and accounted for as described above. Once all such upgrade obligations have been delivered, all accumulated deferred revenue is recognized ratably over the remaining life of the PCS arrangement.
Sales of additional upgrades as optional extras prior to the delivery of all specified upgrade obligations are considered additional elements of the original arrangement and associated revenues are deferred and accounted for as described above. Sales of additional upgrades after delivery of all specified upgrade obligations, as stated in the original contract, are recognized once all revenue recognition criteria applicable to those arrangements are met.
CyberKnife sales with nonlegacy service plans
In fiscal year 2006, the Company began selling CyberKnife systems with PCS contracts that only provide for upgrades when and if they become available. The Company has established VSOE of the fair value of PCS in these circumstances. For arrangements with multiple elements that include the CyberKnife system, installation services, training services and a PCS service agreement, the Company recognizes the CyberKnife system and installation services revenue following installation and acceptance of the system by application of the residual method as prescribed in SOP 98-9 when VSOE of fair value exists for all undelivered elements in the arrangement, including PCS.
Other revenue Japan upgrade services
Other revenue primarily consists of upgrade services revenues related to the sale of specialized services specifically contracted to provide current technology capabilities for units previously sold through a distributor into the Japan market. Some upgrade sales include elements where VSOE of fair value has not been established for the PCS. As a result, for these sales, associated revenues are deferred and recognized ratably over the term of the PCS arrangement, generally four years.
PCS and maintenance services
Service revenue for providing PCS, which includes warranty services, extended warranty services, unspecified when and if available product updates and technical support is deferred and recognized ratably over the service period, generally one year, until no further obligation exists. At the time of sale, the Company provides for the estimated incremental costs of meeting product warranty if the incremental warranty costs are expected to exceed the related service revenues. Training and consulting service revenues that are not deemed essential to the functionality of the CyberKnife system are recognized as such services are performed.
Costs associated with providing PCS and maintenance services are expensed when incurred, except when those costs are related to units where revenue recognition has been deferred. In those cases, the costs are deferred until the recognition of the related revenue and are recognized over the period of revenue recognition.
8
Distributor sales
Sales to third party distributors are evidenced by distribution agreements governing the relationship together with binding purchase orders on a transaction-by-transaction basis. The Company records revenues from sales of CyberKnife systems to distributors based on a sell-through method where revenue is only recognized upon shipment of the product to the end user customer and once all other revenue recognition criteria are met including completion of all obligations under the terms of the purchase order. For sales of upgrades and accessories to distributors, revenue is recognized on either a sell-through or sell-in basis, depending upon the terms of the purchase order and once all revenue recognition criteria are met. These criteria require that persuasive evidence of an arrangement exist, the fees are fixed or determinable, collection of the resulting receivable is probable and there is no right of return.
The Companys agreements with customers and distributors generally do not contain product return rights.
The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the credit-worthiness of the customer. The Company generally does not request collateral from its customers. If the Company determines that collection of a fee is not probable, the Company will defer the fee and recognize revenue upon receipt of cash.
Shared ownership program
The Company also enters into arrangements under its shared ownership program with certain customers. Agreements under the shared ownership program typically have a term of five years, during which the customer has the option to purchase the system, either at the end of the contractual period or in advance, at the customers request, at pre-determined prices. Under the terms of such program, the Company retains title to its CyberKnife system, while the customer has use of the product. The Company generally receives a minimum monthly payment and earns additional revenues from the customer based upon its use of the product. The Company may provide unspecified upgrades to the product during the term of each program when and if available. Upfront non-refundable payments from the customer are deferred and recognized as revenue over the contractual period. Revenues from the shared ownership program are recorded as they become earned and receivable and are included within shared ownership program revenues in the condensed consolidated statements of operations. The Company recognized $876,000 and $1.9 million for the three and six months ended December 31, 2008, respectively, of revenue from the shared ownership program. The Company recognized $3.0 million and $5.4 million for the three and six months ended December 31, 2007, respectively, of revenue from the shared ownership program.
Future minimum revenues under shared ownership arrangements as of December 31, 2008 are as follows (in thousands):
Years ending June 30, |
|
|
|
|
2009 (remaining six months) |
|
$ |
240 |
|
2010 |
|
480 |
|
|
2011 |
|
480 |
|
|
2012 |
|
480 |
|
|
2013 and thereafter |
|
240 |
|
|
Total |
|
$ |
1,920 |
|
Total usage-based fee revenues, which are included in shared ownership program revenue, earned from the CyberKnife systems under the shared ownership program amounted to $753,000 and $1.7 million for the three and six months ended December 31, 2008, respectively, and $2.3 million and $4.0 million for the three and six months ended December 31, 2007, respectively.
Under the terms of the shared ownership program, the customer has the option to purchase the CyberKnife system at pre-determined prices based on the period the system has been in use and considering the lease payments already received. Revenue from such sales is recorded in accordance with the Companys revenue recognition policy, taking into account the PCS and any other elements that might be sold as part of the arrangement. No revenue was recognized from the sale of CyberKnife system units that were formerly a part of the Companys shared ownership program during the three and six months ended December 31, 2008. During the three and six months ended December 31, 2007, $3.4 and $6.5 million of products revenue, respectively, was recognized in the condensed consolidated statement of operations from the sale of two and three CyberKnife system units, respectively, that were formerly part of the Companys shared ownership program.
The CyberKnife systems associated with the Companys shared ownership program are recorded within property and equipment and are depreciated over their estimated useful life of ten years. Depreciation and warranty expense attributable to the CyberKnife shared ownership systems are recorded within cost of shared ownership program.
9
Long-term manufacturing contracts
The Company recognizes revenue and cost of revenue related to long-term manufacturing contracts using contract accounting on the percentage-of-completion method in accordance with SOP No. 81-1, Accounting for Performance of Construction-Type and Certain Production-Type Contracts. Contract revenue of $1.0 million was recorded during the three and six months ended December 31, 2008. Related costs of $1.1 million were recorded during the same periods. No contract revenue or related costs were recorded for the three and six months ended December 31, 2007. The Company recognizes any loss provisions from the total contract in the period such loss is identified. During the three months ended December 31, 2008, increases in projected costs to complete were sufficient to create a loss position for certain projects. As such, an estimated loss provision of $87,000 was recognized during the three and six months ended December 31, 2008. As of December 31, 2008 and June 30, 2008, costs of $628,000 and $1.0 million, respectively, were recorded in deferred cost of revenue related to long-term manufacturing contracts.
Deferred Revenue and Deferred Cost of Revenue
Deferred revenue consists of deferred product revenue, deferred shared ownership program revenue, deferred service revenue and deferred other revenue. Deferred product revenue arises from timing differences between the shipment of product and the satisfaction of all revenue recognition criteria consistent with the Companys revenue recognition policy. Deferred shared ownership program revenue results from the receipt of advance monthly minimum lease payments, which will be recognized ratably over the term of the shared ownership program. Deferred service revenue results from the advance payment for services to be delivered over a period of time, usually one year. Deferred other revenue results primarily from the Japan upgrade services programs and is due to timing differences between the receipt of cash payments for those upgrades and final delivery to the end user customer. Deferred cost of revenue consists of the direct costs associated with the manufacture of units, direct service costs and deferred costs associated with the Japan upgrade services programs for which the revenue has been deferred in accordance with the Companys revenue recognition policies. Deferred revenue, and associated deferred cost of revenue, expected to be realized within one year are classified as current liabilities and current assets, respectively.
Customer Advances
Customer advances represent payments made by customers in advance of product shipment.
Research and Development Costs
Costs related to research, design and development of products are charged to research and development expense as incurred. These costs include direct salary costs for research and development personnel, costs for materials used in research and development activities, costs for outside services and allocated portions of facilities and other corporate costs. The Company has entered into research and clinical study arrangements with selected hospitals, cancer treatment centers, academic institutions and research institutions worldwide. These agreements support the Companys internal research and development capabilities.
Stock-Based Compensation
The Company recognizes stock-based compensation expense in accordance with SFAS No. 123(R), Share-Based Payment, an amendment of FASB Statements Nos. 123 and 95 (SFAS 123R). Under SFAS 123R, the Company estimated the fair value of each option award on the date of grant using the Black-Scholes option-pricing model using the assumptions noted in the table below. Expected volatility was based on the historical volatility of a peer group of publicly traded companies. The expected term of options was based upon the vesting term (for example, 25% on the first anniversary of the vesting start date and 36 equal monthly installments thereafter) and on its partial life history. The risk-free rate for the expected term of the option is based on the U.S. Treasury Constant Maturity rate.
The estimated fair value of the stock options granted was calculated at each date of grant using the Black-Scholes option pricing model, using fair values of common stock between $3.75 and $8.99 per share during the three and six months ended December 31, 2008, and between $12.80 and $29.25 per share during the three and six months ended December 31, 2007. The fair value of the Companys common stock is determined by its closing market price as published by the Nasdaq Global Market. During the three and six months ended December 31, 2008, the Company recognized $2.3 million and $5.8 million, respectively, of stock-based compensation expense for stock options granted to employees. During the three and six months ended December 31, 2007, the Company recognized $3.0 million and $6.2 million, respectively, of stock-based compensation expense for stock options granted to employees. Weighted-average grant date fair values for the three and six months ended December 31, 2008 were $3.90 and $4.62, respectively. Weighted-average grant date fair values for the three and six months ended December 31, 2007 were $10.42 and $9.22, respectively. The following weighted-average assumptions were used to value options granted during the three and six months ended December 31, 2008 and 2007, respectively:
10
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
2008 |
|
2007 |
|
Risk-free interest rate |
|
2.28 |
% |
3.62 |
% |
2.89 |
% |
4.27 |
% |
Dividend yield |
|
|
|
|
|
|
|
|
|
Expected life |
|
6.25 |
|
6.25 |
|
6.25 |
|
6.25 |
|
Expected volatility |
|
65.2 |
% |
59.8 |
% |
63.5 |
% |
60.5 |
% |
During the three and six months ended December 31, 2008, the Company recognized $43,000 and $897,000 of stock-based compensation expense related to accelerated vesting of stock options and restricted stock units, or RSUs, in conjunction with employee separation costs.
In January 2007, in connection with the Companys initial public offering, or IPO, the Board of Directors approved the 2007 Incentive Award Plan (2007 Plan) and 2007 Employee Stock Purchase Plan (ESPP). The ESPP is deemed compensatory and compensation costs are accounted for under SFAS 123R.
Under the ESPP, qualified employees are entitled to purchase common stock at 85% of the fair market value on specified dates. The estimated fair value of ESPP shares are calculated at the date of grant using the Black-Scholes option pricing model, using the fair value of common stock determined by the Companys closing market price on the date of grant, as published by the Nasdaq Global Market. Expected volatility is based on the historical volatility of a peer group of publicly traded companies. The expected term is based upon the offering period of the ESPP. The risk-free rate for the expected term of the ESPP option is based on the U.S. Treasury Constant Maturity rate. For the three and six months ended December 31, 2008, the Company recognized $252,000 and $521,000, respectively, of compensation expense related to its ESPP. For the three and six months ended December 31, 2007, the Company recognized $284,000 and $563,000, respectively, of compensation expense related to its ESPP. The following weighted-average assumptions were used to value ESPP shares at the date of grant:
|
|
Three and Six Months Ended |
|
||
|
|
2008 |
|
2007 |
|
Risk-free interest rate |
|
0.44 |
% |
3.28 |
% |
Dividend yield |
|
|
|
|
|
Expected life |
|
0.50 |
|
0.50 |
|
Expected volatility |
|
85.4 |
% |
58.5 |
% |
In connection with the 2007 Plan, the Company issued RSUs and recognized $1.1 million and $2.2 million of stock-based compensation expense, net of estimated forfeitures, for RSUs granted during the three and six months ended December 31, 2008, respectively. The Company recognized $1.0 million and $1.8 million of stock-based compensation expense, net of estimated forfeitures, for RSUs granted during the three and six months ended December 31, 2007, respectively. Weighted-average grant date fair values for the three and six months ended December 31, 2008 were $6.43 and $6.69, respectively. Weighted-average grant date fair values for the three and six months ended December 31, 2007 were $19.43 and $16.64, respectively.
Tax benefits from tax deductions for exercised options and disqualifying dispositions in excess of the deferred tax asset attributable to stock compensation costs for such options are credited to additional paid-in capital. Realized excess tax benefits for the three and six months ended December 31, 2007 were $382,000 and $718,000, respectively. The Company did not recognize any benefit from stock options for the three and six months ended December 31, 2008.
At December 31, 2008 and June 30, 2008, capitalized stock-based compensation costs of $521,000 and $489,000, respectively, were included as components of inventory and deferred cost of revenue.
Net Income (Loss) Per Common Share
Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of dilutive common shares outstanding during the period. Dilutive shares outstanding are calculated by adding to the weighted shares outstanding any common stock equivalents from outstanding stock options, restricted stock units and warrants based on the treasury stock method. In periods when net income is reported, the calculation of diluted net income per share typically results in lower earnings per share than is calculated using the basic method. In periods when a net loss is reported, potential shares from stock options, restricted stock units and warrants are not included in the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, the calculation of basic and diluted net loss per share results in the same value.
11
For the three and six months ended December 31, 2008, basic net income (loss) per share was based on weighted-average shares of 55,064,326 and 54,844,804, respectively. For the three and six months ended December 31, 2007, basic net income per share was based on weighted-average shares of 54,736,764 and 54,380,054, respectively. For the three and six months ended December 31, 2008, diluted net income (loss) per share was based on weighted-average shares of 58,267,253 and 54,844,804, respectively. For the three and six months ended December 31, 2007, diluted net income per share was based on weighted-average shares of 61,292,905 and 61,256,532, respectively. The number of anti-dilutive shares excluded from the calculation of diluted income (loss) per share was as follows:
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
2008 |
|
2007 |
|
Options to purchase common stock |
|
3,545,031 |
|
959,263 |
|
8,833,881 |
|
793,469 |
|
Restricted stock units |
|
706,668 |
|
629,092 |
|
738,643 |
|
654,250 |
|
|
|
4,251,700 |
|
1,588,355 |
|
9,572,524 |
|
1,447,719 |
|
The following table sets forth the basic and diluted per share computations:
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
|
||||||||
|
|
2008 |
|
2007 |
|
2008 |
|
2007 |
|
||||
Numerator: |
|
|
|
|
|
|
|
|
|
||||
Net income (loss) (in thousands) |
|
$ |
1,350 |
|
$ |
2,343 |
|
$ |
(1,829 |
) |
$ |
4,608 |
|
Denominator: |
|
|
|
|
|
|
|
|
|
||||
Basic weighted-average shares outstanding |
|
55,064,326 |
|
54,736,764 |
|
54,844,804 |
|
54,380,054 |
|
||||
Stock options and restricted stock units |
|
3,202,927 |
|
6,556,141 |
|
|
|
6,876,478 |
|
||||
Diluted weighted-average shares of common stock and equivalents outstanding |
|
58,267,253 |
|
61,292,905 |
|
54,844,804 |
|
61,256,532 |
|
||||
Basic net income (loss) per share: |
|
$ |
0.02 |
|
$ |
0.04 |
|
$ |
(0.03 |
) |
$ |
0.08 |
|
Diluted net income (loss) per share: |
|
$ |
0.02 |
|
$ |
0.04 |
|
$ |
(0.03 |
) |
$ |
0.08 |
|
Income and Other Taxes
The Company is required to estimate its income taxes in each of the tax jurisdictions in which it operates prior to the completion and filing of tax returns for such periods. This process involves estimating actual current tax expense together with assessing temporary differences in the treatment of items for tax purposes versus financial accounting purposes that may create net deferred tax assets and liabilities. The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of the Companys assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses, research and development credit carry forwards and temporary differences.
The Company records a valuation allowance to reduce its deferred tax assets to the amount the Company believes is more likely than not to be realized. Because of the uncertainty of the realization of the deferred tax assets, the Company has recorded a full valuation allowance against its domestic and certain foreign net deferred tax assets.
The Company had $1.4 million of unrecognized tax benefits as of June 30, 2008, all of which would affect its income tax expense if recognized. The unrecognized tax benefits mainly relate to federal and state net operating losses and research tax credits. In the three and six months ended December 31, 2008, none of the related benefits have been realized. The Company files income tax returns in the U.S. federal jurisdiction, and various states and foreign jurisdictions. Due to attributes being carried forward, the statute of limitations remains open for the U.S. federal jurisdiction and domestic states for tax years from 1999 forward. The statute of limitations in France remains open from 2005 and Hong Kong remains open from 2002. The Companys subsidiary, Accuray Europe SARL, incurred non-income tax related penalties and interest of $112,000 as the result of the French tax audit for the tax years 2005 to 2007, recorded in other income, net for the three and six months ended December 31, 2008.
In accordance with SFAS No.109, Accounting for Income Taxes, the Company classifies interest and penalties as a component of tax expense. Such interest and penalties were immaterial as of December 31, 2008.
The Company adopted the provisions of Emerging Issues Task Force (EITF) Issue No. 06-03, How Taxes Collected from Customers and Remitted to Government Authorities Should Be Presented in the Income Statement (That Is, Gross versus Net Presentation) (EITF 06-03), effective January 1, 2007. EITF 06-03 allows companies to choose either the gross basis or net basis of income statement presentation for taxes collected from customers and remitted to governmental authorities and requires companies to disclose such policy. The Company applies the net basis presentation for taxes collected from customers and remitted to government authorities.
12
Segment Information
The Company has determined that it operates in only one segment in accordance with SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information (SFAS 131) as it only reports profit and loss information on an aggregate basis to its chief operating decision maker. The Companys long-lived assets maintained outside the United States are not material.
Revenue by geographic region is based on the shipping addresses of the Companys customers. The following summarizes revenue by geographic region (in thousands):
|
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
|
||||||||
|
|
2008 |
|
2007 |
|
2008 |
|
2007 |
|
||||
United States (including Puerto Rico) |
|
$ |
35,564 |
|
$ |
31,782 |
|
$ |
77,816 |
|
$ |
61,550 |
|
Europe |
|
10,853 |
|
3,306 |
|
12,526 |
|
4,555 |
|
||||
Asia (excluding Japan) |
|
8,661 |
|
15,413 |
|
14,754 |
|
26,966 |
|
||||
Japan |
|
2,559 |
|
1,537 |
|
8,398 |
|
7,613 |
|
||||
Total |
|
$ |
57,637 |
|
$ |
52,038 |
|
$ |
113,494 |
|
$ |
100,684 |
|
Recent Accounting Pronouncements
In December 2008, the FASB issued FASB Staff Position (FSP) FAS 140-4 and Financial Interpretations (FIN) 46(R)-8, Disclosures by Public Entities (Enterprises) about Transfers of Financial Assets and Interest is in Variable Interest Entities (FSP FAS 140-4). This disclosure-only FSP improves the transparency of transfers of financial assets and an enterprises involvement with variable interest entities, including qualifying special-purpose entities. This FSP is effective for the first reporting period (interim or annual) ending after December 15, 2008, with earlier application encouraged. The adoption of FSP FAS 140-4 and FIN 46(R)-8 did not have a material impact on the Companys condensed consolidated financial statements.
In October 2008, the FASB issued FSP No. FAS 157-3, Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active (FSP FAS 157-3). FSP FAS 157-3 provides examples to illustrate key considerations in determining the fair value of a financial asset when the market for that financial asset is not active. FSP FAS 157-3 was effective upon issuance and did not have a material impact on the Companys consolidated financial statements.
3. FINANCIAL INSTRUMENTS
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial LiabilitiesIncluding an amendment of FASB Statement No. 115 (SFAS 159). SFAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value, with changes in fair value recognized in earnings each reporting period. The election, called the fair value option, will enable entities to achieve an offset accounting effect for changes in fair value of certain related assets and liabilities without having to apply complex hedge accounting provisions. In November 2008, the Company entered into an agreement (Rights Agreement) with UBS, the financial institution broker, which provides the Company with ARS Rights (Rights) to sell its ARS at par value to UBS at any time during the period June 30, 2010 through July 2, 2012. These Rights are a separate freestanding instrument accounted for separately from the ARS, and are registered, nontransferable securities accounted for as a put option initially recorded at fair value. Under the Rights Agreement, UBS may, at its discretion, trade the ARS at any time through July 2, 2012 without prior notice to the Company and must pay the Company par value for the ARS within one day of the sale transaction settlement. Additionally, UBS offered a no net cost loan to the Company up to the market value of the ARS as determined by UBS until June 30, 2010 and the Company agreed to release UBS from certain potential claims related to the collateralized ARS in certain specified circumstances. During the three months ended December 31, 2008, the Company elected fair value accounting for the put option recorded in connection with the Rights Agreement. This election was made in order to mitigate volatility in earnings caused by accounting for the purchased put option and underlying ARS under different methods. The initial election of fair
13
value resulted in a $3.3 million gain included in Other income, net for the put option asset which is recorded in long-term trading securities.
Due to the Company entering into this Rights Agreement with UBS and enabling UBS to sell the ARS at any time, the ARS previously reported as available-for-sale have been transferred to trading securities and are classified as long-term trading securities on the condensed consolidated balance sheet as of December 31, 2008. Due to the change in classification to trading securities at the time of entering into the Rights Agreement, the Company transferred the previously accumulated unrealized loss of $3.8 million from Accumulated other comprehensive income (loss) to Other income, net and recorded an additional unrealized loss of $407,000 relating to the change in fair value of the trading securities from November 2008 through the end of the reporting period in Other income, net for a total unrealized loss of $4.2 million included in net income for the three and six months ended December 31, 2008. The total loss of $4.2 million was partially offset by a $3.3 million gain recognized on the put option, for a net loss of $860,000 included in Other income, net.
The Company adopted SFAS No. 157, Fair Value Measurements (SFAS 157), subject to the deferral provisions of FSP FAS 157-2, Effective Date of FASB Statement No. 157, on July 1, 2008. This standard defines fair value, establishes a framework for measuring fair value and expands disclosure requirements about fair value measurements. SFAS 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy prescribed by SFAS 157 contains three levels as follows:
Level 1 Unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date.
Level 2 Other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including:
· Quoted prices for similar assets or liabilities in active markets;
· Quoted prices for identical or similar assets in non-active markets;
· Inputs other than quoted prices that are observable for the asset or liability; and
· Inputs that are derived principally from or corroborated by other observable market data.
Level 3 Unobservable inputs that cannot be corroborated by observable market data and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize managements estimates of market participant assumptions.
Assets and Liabilities that are Measured at Fair Value on a Recurring Basis
The fair value hierarchy requires the use of observable market data when available. In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Companys assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The following table sets forth by level within the fair value hierarchy the Companys financial assets that were accounted for at fair value on a recurring basis at December 31, 2008, according to the valuation techniques the Company used to determine their fair values.
|
|
|
|
Fair Value Measurements |
|
||||||||
|
|
Fair Value at |
|
Using Inputs Considered as |
|
||||||||
|
|
December 31, 2008 |
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
||||
|
|
(in thousands) |
|
||||||||||
Money market funds |
|
$ |
25,039 |
|
$ |
25,039 |
|
$ |
|
|
$ |
|
|
Corporate notes |
|
22,308 |
|
|
|
22,308 |
|
|
|
||||
Commercial paper |
|
21,569 |
|
|
|
21,569 |
|
|
|
||||
U.S. government and governmental agency obligations |
|
59,312 |
|
|
|
59,312 |
|
|
|
||||
Auction-rate securities |
|
18,224 |
|
|
|
|
|
18,224 |
|
||||
Put option |
|
3,316 |
|
|
|
|
|
3,316 |
|
||||
Total |
|
$ |
149,768 |
|
$ |
25,039 |
|
$ |
103,189 |
|
$ |
21,540 |
|
The table below presents a reconciliation of all assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the six months ended December 31, 2008. The Company classifies financial instruments in Level 3 of the fair value hierarchy when there is reliance on at least one significant unobservable input to the valuation model. In addition to these unobservable inputs, the valuation models for Level 3 financial instruments typically also rely on a number of inputs that are readily observable either directly or indirectly. Thus, the gains and losses presented below include changes in the fair value related to both observable and unobservable inputs.
14
|
|
Fair Value Measurements Using Significant |
|
|
|
|
(in thousands) |
|
|
Balance at June 30, 2008 |
|
$ |
21,509 |
|
Change in temporary valuation adjustment recorded in Accumulated other Comprehensive Income during the fiscal year ended June 30, 2008 |
|
891 |
|
|
Unrealized loss included in earnings (1) |
|
(4,176 |
) |
|
Recognition of put option |
|
3,316 |
|
|
Balance at December 31, 2008 |
|
$ |
21,540 |
|
(1) Represents the amount of total losses for the period included in earnings relating to assets still held on December 31, 2008.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument:
Money market funds. Money market funds are classified as cash and cash equivalents on the Companys condensed consolidated balance sheet.
Corporate notes. Corporate notes are floating-rate obligations that are payable on demand. These are classified as available-for-sale within short-term marketable securities on the Companys condensed consolidated balance sheet. The market approach was used to value the Companys variable-rate demand notes. The Company classified these securities as Level 2 instruments due to either its usage of observable market prices in less active markets or, when observable market prices were not available, its use of non-binding market prices that are corroborated by observable market data or quoted market prices for similar instruments.
Commercial paper. Commercial paper is an unsecured, short-term debt instrument issued by corporations and financial institutions that generally mature within 270 days. The entire $21.6 million held in commercial paper is classified as short-term marketable securities on the Companys condensed consolidated balance sheet. The portion in cash and cash equivalents represents highly liquid debt instruments with insignificant interest rate risk and original maturities of ninety days or less. The market approach was used to value the Companys commercial paper. The Company classified these securities as Level 2 instruments due to either its usage of observable market prices in less active markets or, when observable market prices were not available, its use of non-binding market prices that are corroborated by observable market data or quoted market prices for similar instruments.
U.S. government and governmental agency obligations. U.S. government and governmental agency obligations are issued by state and local governments and other governmental entities such as authorities or special districts. These are classified as short-term marketable securities on the Companys condensed consolidated balance sheet. The market approach was used to value the Companys U.S. government and governmental agency obligations. The Company classified these securities as Level 2 instruments due to either its usage of observable market prices in less active markets or, when observable market prices were not available, its use of non-binding market prices that are corroborated by observable market data or quoted market prices for similar instruments.
Auction-rate securities. As of December 31, 2008, there was insufficient observable market information available to determine the fair value of the Companys ARS. Prior to December 31, 2008, the Company estimated Level 3 fair values for these securities based on the financial institutions brokers valuations. The financial institution broker valued student loan ARS as floating rate notes with three pricing inputs: the coupon, the current discount margin or spread, and the maturity. The coupon was generally assumed to equal the maximum rate allowed under the terms of the instrument, the current discount margin was based on an assessment of observable yields on instruments bearing comparable risks, and the maturity was based on an assessment of the terms of the underlying instrument and the potential for restructuring the ARS. The primary unobservable input to the valuation was the maturity assumption which was set at five years for the majority of ARS instruments. Through January 6, 2008, the ARS were valued at par value due to the frequent resets that historically occurred through the auction process.
As of December 31, 2008, the Company engaged a third party valuation service to model Level 3 fair value using an income approach. The Company reviewed the methodologies employed by the third party models. This included a review of all relevant data
15
inputs and the appropriateness of key model assumptions.
The pricing assumptions for the ARS included the coupon rate, the estimated time to liquidity, current market rates for publicly traded corporate debt of similar credit rating and an adjustment for lack of liquidity. The coupon rate was assumed to equal the stated maximum auction rate being received, which is determined based on the applicable 91-day U.S. Treasury rate plus 1.20% premium according to provisions outlined in each securitys agreement. The estimated time to liquidity was 3.5 years based on (i) expectations from industry brokers for liquidity in the market and (ii) the period over which UBS and other broker-dealers that had issued ARS have agreed to redeem certain ARS at par value.
The put option (see above) gives the Company the right to sell the ARS to UBS for a price equal to par value during the period June 30, 2010 to July 2, 2012, providing liquidity for the ARS sooner than the estimated 3.5 years. As the Company plans to exercise the put option on or around June 30, 2010, the value of the put option lies in (i) the ability to sell the securities thereby creating liquidity approximately two years before the ARS market is expected to become liquid and (ii) the avoidance of receiving below-market coupon rate while the security is illiquid and auctions are failing. The fair value of the put option represents the difference between the ARS with an estimated time to liquidity of 3.5 years and the ARS with an estimated time to liquidity of 1.5 years as the put option allows for the acceleration of liquidity and the avoidance of a below market coupon rate over the 1.5 year time period.
4. BALANCE SHEET COMPONENTS
Accounts receivable, net
Accounts receivable, net consists of the following (in thousands):
|
|
December 31, 2008 |
|
June 30, 2008 |
|
||
Accounts receivable |
|
$ |
40,329 |
|
$ |
33,264 |
|
Unbilled fees and services |
|
801 |
|
681 |
|
||
|
|
41,130 |
|
33,945 |
|
||
Less: Allowance for doubtful accounts |
|
(195 |
) |
(27 |
) |
||
Accounts receivable, net |
|
$ |
40,935 |
|
$ |
33,918 |
|
Inventories
Inventories are stated at the lower of cost (first-in, first-out) or market, and consist of the following (in thousands):
|
|
December 31, 2008 |
|
June 30, 2008 |
|
||
Raw materials |
|
$ |
9,363 |
|
$ |
8,853 |
|
Work-in-process |
|
10,192 |
|
3,967 |
|
||
Finished goods |
|
4,525 |
|
10,227 |
|
||
Total inventories |
|
$ |
24,080 |
|
$ |
23,047 |
|
Property and Equipment, net
Property and equipment, net consists of the following (in thousands):
|
|
December 31, 2008 |
|
June 30, 2008 |
|
||
Furniture and fixtures |
|
$ |
3,530 |
|
$ |
3,379 |
|
Computer and office equipment |
|
7,457 |
|
6,912 |
|
||
Leasehold improvements |
|
7,555 |
|
7,579 |
|
||
Machinery and equipment |
|
13,586 |
|
12,287 |
|
||
CyberKnife shared ownership systems |
|
4,054 |
|
3,951 |
|
||
|
|
36,182 |
|
34,108 |
|
||
Less: Accumulated depreciation and amortization |
|
(20,024 |
) |
(16,968 |
) |
||
Property and equipment, net |
|
$ |
16,158 |
|
$ |
17,140 |
|
Depreciation and amortization expense related to property and equipment for the three and six months ended December 31, 2008 was $1.6 million and $3.2 million, respectively. Depreciation and amortization expense related to property and equipment for the three and six months ended December 31, 2007 was $2.0 million and $3.8 million, respectively. Accumulated depreciation related to
16
the CyberKnife systems attributable to the shared ownership program at December 31, 2008 and June 30, 2008 was $1.8 million and $1.6 million, respectively.
5. INVESTMENT
On July 29, 2008, the Company and Morphormics, Inc. (Morphormics) entered into a Stock Purchase Agreement pursuant to which the Company agreed to purchase 120,000 shares of Morphormics Series C Preferred Stock at $12.50 per share, for a total purchase price of $1.5 million. In exchange, Morphormics granted the Company a non-exclusive worldwide license to integrate several of its software products into the Companys treatment planning software. The equity investment afforded the Company a voting interest of approximately 18% in Morphormics. The Companys equity is considered to be at risk and is deemed not sufficient to finance Morphormics current product development activities without additional subordinated financial support. In addition, the Company is deemed to be Morphormics primary beneficiary; therefore, it would absorb a majority of expected losses. Pursuant to guidance in FASB Interpretation 46(R), Consolidation of Variable Interest Entities (FIN 46(R)), the Company is required to consolidate Morphormics in its financial results under GAAP. The consolidation of Morphormics assets and liabilities did not have a material effect on the Companys condensed consolidated balance sheet at December 31, 2008. Subsequent to July 29, 2008, the Company has recorded losses of $553,000 on its investment in Morphormics. The remaining $947,000 of the Companys investment remains at risk as of December 31, 2008.
6. GOODWILL AND OTHER PURCHASED INTANGIBLES
In accordance with SFAS No. 142, Goodwill and Other Intangible Assets (SFAS 142), goodwill and other intangible assets with indefinite lives are not amortized. Intangible assets with determinable useful lives are amortized on a straight line basis over their useful lives. SFAS 142 requires that the Company perform an annual test for impairment of intangible assets with indefinite lives, and interim tests if indications of potential impairment exist. The Company performed the annual test for impairment in December 2008 concluding that there was no impairment of goodwill.
The amortization expense relating to intangible assets for both the three and six months ended December 31, 2008 and 2007 was approximately $65,000 and $129,000, respectively. The following represents the gross carrying amounts and accumulated amortization of amortized intangible assets at December 31, 2008 and June 30, 2008 (in thousands):
|
|
December 31, 2008 |
|
June 30, 2008 |
|
||
Complete technology |
|
$ |
1,740 |
|
$ |
1,740 |
|
Customer contract / relationship |
|
70 |
|
70 |
|
||
|
|
1,810 |
|
1,810 |
|
||
Less: Accumulated amortization |
|
(1,013 |
) |
(884 |
) |
||
Intangible assets, net |
|
$ |
797 |
|
$ |
926 |
|
The following table represents the estimated useful life of the intangible assets subject to amortization:
|
|
Years |
|
Amortized intangible assets: |
|
|
|
Complete technology |
|
7.0 |
|
Customer contract / relationship |
|
7.0 |
|
The estimated future amortization expense of purchased intangible assets as of December 31, 2008, is as follows (in thousands):
2009 (remaining six months) |
|
$ |
130 |
|
2010 |
|
258 |
|
|
2011 |
|
258 |
|
|
2012 |
|
151 |
|
|
Total |
|
$ |
797 |
|
7. COMMITMENTS AND CONTINGENCIES
Royalty Agreements
In July 1997, the Company entered into a license and royalty agreement with Stanford University (Stanford) under which the Company has a non-exclusive license to use certain technology. Under this agreement, the Company is obligated to pay Stanford up to $10,000 for each CyberKnife system sold that includes the licensed technology, with the stipulation that the Company must make minimum annual payments of $25,000. Royalty expense recorded in cost of revenue or deferred cost of revenue was $55,000 and $100,000 for the three and six months ended December 31, 2008, respectively. Royalty expense recorded in cost of revenue or deferred cost of revenue was $50,000 and $80,000 for the three and six months ended December 31, 2007, respectively. At December 31, 2008 and June 30, 2008, the Company had accrued amounts of approximately $55,000 and $40,000, respectively, included in other accrued liabilities in the condensed consolidated balance sheets relating to this license and royalty agreement.
17
In January 1999, the Company entered into a license and royalty agreement with Professor Dr. Achim Schweikard (Schweikard) of the University of Munich. Under this agreement, the Company has a non-exclusive license to use certain technology. The Company is obligated to pay Schweikard up to $5,000 for each CyberKnife system sold that includes the licensed technology, with the stipulation that the Company must make minimum annual payments of $5,000. Royalty expense under this agreement recorded in cost of revenue or deferred cost of revenue was $55,000 and $100,000 for the three and six months ended December 31, 2008, respectively. Royalty expense under this agreement recorded in cost of revenue or deferred cost of revenue was $55,000 and $85,000 for the three and six months ended December 31, 2007, respectively. At December 31, 2008 and June 30, 2008, the Company had accrued amounts of approximately $55,000 and $40,000, respectively, included in other accrued liabilities in the condensed consolidated balance sheets relating to this license and royalty agreement.
In March 2007, the Company entered into a license and royalty agreement with Deutsches Krebsforschungszentrum (DKFZ), a German cancer research center. Under this agreement, the Company has a non-exclusive license to use certain technology. The Company is obligated to pay DKFZ $12,500 for each CyberKnife system sold that includes the licensed technology, with the stipulation that the Company must make minimum annual payments of $50,000. Royalty expense under this agreement recorded in cost of revenue or deferred cost of revenue was $100,000 and $175,000 for the three and six months ended December 31, 2008, respectively. No royalty expense was recorded under this agreement during the three and six months ended December 31, 2007. At December 31, 2008 and June 30, 2008, the Company had accrued amounts of approximately $212,500 and $38,000, respectively, included in other accrued liabilities in the condensed consolidated balance sheets relating to this license and royalty agreement.
Contingencies
From time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of business. Management does not believe the final disposition of these matters will have a material adverse effect on the financial position, results of operations or future cash flows of the Company.
Software License Indemnity
Under the terms of the Companys software license agreements with its customers, the Company agrees that in the event the software sold infringes upon any patent, copyright, trademark, or any other proprietary right of a third party, it will indemnify its customer licensees, against any loss, expense, or liability from any damages that may be awarded against its customer. The Company includes this infringement indemnification in all of its software license agreements and selected managed services arrangements. In the event the customer cannot use the software or service due to infringement and the Company cannot obtain the right to use, replace or modify the license or service in a commercially feasible manner so that it no longer infringes, then the Company may terminate the license and provide the customer a refund of the fees paid by the customer for the infringing license or service. The Company has recorded no liability associated with this indemnification, as it is not aware of any pending or threatened actions that are probable losses.
8. STOCK PLANS
In August 2007, the Company announced that the Board of Directors had approved a stock repurchase plan that authorized the Company to repurchase shares of its common stock. Under the plan, the Company has the ability to acquire up to $25.0 million of common shares in the open market over a period of one year. No shares were repurchased during the three and six months ended December 31, 2008. As of December 31, 2008, the Company has repurchased 2,140,018 shares of its common stock for $24.0 million. Such shares were not retired nor returned to the status of authorized, unissued shares. Accordingly, such shares remain issued and classified as treasury stock as of December 31, 2008. The Company accounts for its treasury stock under the par value method. At December 31, 2008, the aggregate par value of the Companys treasury stock was immaterial. The stock repurchase plan expired in August 2008 and was not renewed by the Board of Directors.
Stock Option Plans
In 1993, the Companys stockholders approved the 1993 Stock Option Plan (the 1993 Plan). Under the 1993 Plan, the Board of Directors is authorized to grant options to purchase shares of common stock at fair value, as determined by the Board of Directors, to employees, directors and consultants for up to 1,744,268 shares.
In 1998, the Companys stockholders approved the 1998 Equity Incentive Plan (the 1998 Plan). Under the 1998 Plan, the Board of Directors is authorized to grant options to purchase shares of common stock to employees, directors and consultants for up to 14,100,000 shares.
In 2007, the Board of Directors approved the 2007 Incentive Award Plan (the 2007 Plan). Under the 2007 Plan, the Board of Directors is authorized to award stock-based grants to employees, directors, and consultants for up to 4,500,000 shares. As of December 31, 2008, the 1993 Plan and the 1998 Plan continued to remain in effect with respect to options previously granted under such plans; however, options can no longer be granted from the 1993 and 1998 Plans.
18
Only employees are eligible to receive incentive stock options. Non-employees may be granted non-qualified options. The Board of Directors has the authority to set the exercise price of all options granted, subject to the exercise price of incentive stock options being no less than 100% of the fair value of a share of common stock on the date of grant; and no less than 85% of the fair value for non-qualified stock options.
Generally, the Companys outstanding options vest at a rate of 25% per year. However, certain options granted to certain employees vest based upon performance. Continued vesting typically terminates when the employment or consulting relationship ends.
The maximum term of the options granted to persons who own at least 10% of the voting power of all outstanding stock on the date of grant is 5 years. The maximum term of all other options is 10 years.
The aggregate intrinsic value in the table below represents the total pretax intrinsic value (the difference between the fair value of the Companys common stock as of the end of the reporting period of $4.90 and the exercise price for stock options) that would have been received by option holders if all options had been exercised on December 31, 2008. The total intrinsic value of options exercised in the three and six months ended December 31, 2008 was approximately $519,000 and $1.8 million, respectively. The total intrinsic value of options exercised in the three and six months ended December 31, 2007 was approximately $8.1 million and $17.6 million, respectively. Cash received from option exercises for the three and six months ended December 31, 2008 was $1.8 million and $2.7 million, respectively. Cash received from option exercises for the three and six months ended December 31, 2007 was $1.0 million and $2.5 million, respectively. Option activity during the six months ended December 31, 2008 was as follows:
|
|
|
|
|
|
Weighted |
|
|
|
||
|
|
|
|
|
|
average |
|
Aggregate |
|
||
|
|
|
|
Weighted |
|
remaining |
|
intrinsic |
|
||
|
|
Options |
|
average |
|
contractual |
|
value as of |
|
||
|
|
outstanding |
|
exercise price |
|
life (years) |
|
December 31, 2008 |
|
||
Balance at June 30, 2008 |
|
9,212,831 |
|
$ |
5.70 |
|
|
|
|
|
|
Options granted |
|
905,630 |
|
$ |
7.57 |
|
|
|
|
|
|
Options forfeited |
|
(523,145 |
) |
$ |
12.34 |
|
|
|
|
|
|
Options exercised |
|
(761,435 |
) |
$ |
3.54 |
|
|
|
|
|
|
Balance at December 31, 2008 |
|
8,833,881 |
|
$ |
5.69 |
|
6.06 |
|
$ |
15,460,793 |
|
Vested or Expected to vest at December 31, 2008 |
|
8,565,423 |
|
$ |
5.54 |
|
5.97 |
|
$ |
15,454,162 |
|
Exercisable at December 31, 2008 |
|
6,606,463 |
|
$ |
4.08 |
|
5.15 |
|
$ |
15,356,562 |
|
As of December 31, 2008, there was approximately $21.2 million, net of estimated forfeitures, of unrecognized compensation cost related to unvested stock options which is expected to be recognized over a weighted-average period of 2.3 years. The Companys current practice is to issue new shares to satisfy share option exercises. The total fair value of shares vested during the three and six months ended December 31, 2008 was $2.5 million and $6.4 million, respectively. The total fair value of shares vested during the three and six months ended December 31, 2007 was $3.2 million and $8.0 million, respectively.
The weighted average grant date fair values of options granted were $3.90 and $4.62 per share for the three and six months ended December 31, 2008, respectively. The weighted average grant date fair values of options granted were $10.42 and $9.22 per share for the three and six months ended December 31, 2007, respectively.
Employee Stock Purchase Plan
Under the Employee Stock Purchase Plan, or ESPP, the Company is authorized to issue up to 1,000,000 shares of common stock. Qualified employees may purchase shares of common stock through payroll deductions at a price per share that is 85% of the lesser of the fair market value of the Companys common stock as of the beginning of an applicable offering period or the applicable purchase date, with purchases generally occurring every six months. Employees payroll deductions may not exceed 10% of their salary. Employees may purchase up to 2,500 shares per period provided that the value of the shares purchased in any calendar year may not exceed $25,000, as calculated pursuant to the purchase plan.
The ESPP was initiated in February 2007. As of December 31, 2008, there was approximately $446,000 of unrecognized compensation cost related to the ESPP, which is expected to be recognized over the next five months.
19
Restricted Stock Units
RSUs generally vest at a rate of 25% per year. However, certain restricted stock units granted to certain employees vest 10% upon the first anniversary year of the grant date, 20% upon the second anniversary year of the grant date, 30% upon the third anniversary year of the grant date and 40% upon the fourth anniversary year of the grant date. Continued vesting typically terminates when the employment relationship ends.
As of December 31, 2008, there was approximately $15.1 million of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted-average period of 2.4 years. Restricted stock unit activity for the six months ended December 31, 2008 was as follows:
|
|
Number of |
|
Weighted Average Grant |
|
|
Unvested resticted stock units at June 30, 2008 |
|
724,034 |
|
$ |
23.43 |
|
Restricted stock units granted |
|
135,555 |
|
$ |
6.69 |
|
Forfeitures |
|
(92,380 |
) |
$ |
23.39 |
|
Releases |
|
(28,566 |
) |
$ |
6.25 |
|
Unvested resticted stock units at December 31, 2008 |
|
738,643 |
|
$ |
20.54 |
|
9. RELATED PARTY TRANSACTIONS
The Company recognized related party revenue of $229,000 and $199,000 during the three months ended December 31, 2008 and 2007, respectively, and $427,000 and $369,000 during the six months ended December 31, 2008 and 2007, respectively, relating to products and services provided to Stanford. The Companys former Chief Executive Officer, Dr. John R. Adler, Jr., is an active member of the faculty at Stanford. Currently, he is a member of the Board of Directors and he holds the position of Professor of Neurosurgery and Radiation Oncology at Stanford. At December 31, 2008 and June 30, 2008, amounts of $713,000 and $231,000, respectively, were recorded as deferred revenue and advances relating to related party payments made by Stanford. At December 31, 2008, $6,000 was due from Stanford. At June 30, 2008, no related party amounts were due from Stanford. The Company recorded $29,000 and $0 of expense during the three months ended December 31, 2008 and 2007, respectively, and $57,000 and $0 of expense during the six months ended December 31, 2008 and 2007, respectively, relating to research grants with Stanford to support customer studies related to the Companys CyberKnife systems. The Company also has a license agreement with Stanford as disclosed in Note 7.
In April 2007, the Company entered into a new consulting agreement with Dr. Adler, which terminated any prior consulting agreements. Under this consulting agreement, Dr. Adler was entitled to receive a maximum compensation of $149,100 per year, payable at the beginning of each quarter beginning on April 1, 2007.
In April 2008, the Company entered into a new consulting agreement with Dr. Adler, which terminated the prior consulting agreements discussed above. Under the new consulting agreement, Dr. Adler is entitled to receive a maximum compensation of $167,100 per year, payable in quarterly installments at the beginning of each quarter beginning on April 1, 2008. This agreement has a term of one year and will renew for successive one-year periods, unless either party provides 30 days written notice of termination prior to the expiration of each one-year period. The Company recognized consulting expense for Dr. Adler of $42,000 and $84,000 for the three and six months ended December 31, 2008, respectively, and $37,000 and $75,000 during the three and six months ended December 31, 2007, respectively, pursuant to these agreements.
The Company recognized no related party revenue during the three and six months ended December 31, 2008 relating to products and services provided to Meditec. The Company recognized $0 and $1.2 million during the three and six months ended December 31, 2007, respectively, relating to products and services provided to Meditec. Meditecs parent, Marubeni Corporation, was a common stockholder of the Company. Marubeni Corporation transferred its interest in the Company during September 2007 and is no longer a stockholder of record of the Company as of September 30, 2008. At December 31, 2008 and June 30, 2008, no related party amounts were recorded as deferred revenue or advances relating to related party payments made by Meditec for products and services. At December 31, 2008 and June 30, 2008, no amounts were due from Meditec.
10. SECURED CREDIT LINE
In November 2008, the Company obtained a line of credit with the financial institution broker in conjunction with the Rights agreement (see Note 3). The line of credit is due on demand and allows for borrowings as determined by the financial institution broker. Advances under this agreement bear interest with interest payments payable monthly. No borrowings were outstanding at December 31, 2008.
To the extent that there are borrowings outstanding under the line of credit, the following provisions will apply.All interest, dividends, distributions, premiums, other income and payments received into the ARS investment account at the financial institution broker will be automatically transferred to the financial institution broker as payments on the line of credit. Additionally, proceeds from any liquidation, redemption, sale or other disposition of all or part of the ARS will be automatically transferred to the financial institution broker as payments. If these payments are insufficient to pay all accrued interest by the monthly due date, then the financial institution broker will either require the Company to make additional interest payments or, at the financial institution brokers discretion, capitalize unpaid interest as an additional advance. The financial institution brokers intent is to cause the interest rate payable by the Company to be
20
equal to the weighted average interest or dividend rate payable to the Company on the ARS pledged as collateral. Upon cancellation of the line of credit, the Company will be reimbursed for any amount paid in interest on the line of credit that exceeds the income on the ARS.
Advances on this line of credit may be used to fund working capital requirements, capital expenditures or other general corporate purposes, except that they may not be used to purchase, trade or carry any securities or to repay debt incurred to purchase, trade or carry any securities.
11. SUBSEQUENT EVENT
On January 29, 2009, the Company announced a Workforce Alignment Plan (the Plan) to reduce headcount and improve efficiency and productivity. As a result of the Plan, the Company reduced its headcount by approximately 60 positions or approximately 13 percent of the Companys U.S. workforce. Most of the affected jobs are located at the Companys Sunnyvale, CA headquarters. All employees affected by the Plan were notified on January 28, 2009. The Company will record restructuring-related charges of approximately $1.7 million throughout the remainder of the fiscal year ending June 30, 2009 in connection with the Plan, comprised mainly of employee severance pay expenses. The Company estimates that the future savings in employment related expenses will be approximately $8.7 million per year. Due to severance pay and the timing of employment terminations, limited savings will begin in the fourth fiscal quarter of 2009 with the full benefit starting in the first quarter of fiscal 2010.
21
Item 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition as of December 31, 2008 and results of operations for the three and six months ended December 31, 2008 and 2007 should be read together with our financial statements and related notes included elsewhere in this report. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. All forward-looking statements included in this report are based on information available to us on the date of this report, and we assume no obligation to update any forward-looking statements contained in this report. These forward-looking statements involve risks and uncertainties, and our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements on the basis of several factors, including those that we discuss in Risk Factors, set forth in Part I, Item 1A, of our annual report on Form 10-K for the fiscal year ended June 30, 2008. We encourage you to read that section carefully.
In this report, Accuray, the Company, we, us, and our refer to Accuray Incorporated.
Overview
We have developed the first and only commercially available intelligent robotic radiosurgery system, the CyberKnife system, designed to treat solid tumors anywhere in the body as an alternative to traditional surgery. The CyberKnife system combines continuous image-guidance technology with a compact linear accelerator that has the ability to move in three dimensions according to the treatment plan. Our image-guidance technology continuously acquires images to track a tumors location and transmits any position corrections to the robotic arm prior to delivery of each dose of radiation. Our compact linear accelerator, or linac, is a compact radiation treatment device that uses microwaves to accelerate electrons to create high-energy X-ray beams to destroy the tumor. This combination, which we refer to as intelligent robotics, extends the benefits of radiosurgery to the treatment of tumors anywhere in the body. The CyberKnife system autonomously tracks, detects and corrects for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation typically with sub-millimeter accuracy. The CyberKnife procedure requires no anesthesia, can be performed on an outpatient basis and allows for the treatment of patients who otherwise would not have been treated with radiation or who may not have been good candidates for surgery. In addition, the CyberKnife procedure avoids many of the potential risks and complications that are associated with other treatment options and is more cost effective than traditional surgery.
In July 1999, we obtained 510(k) clearance from the FDA to market the CyberKnife system for the treatment of tumors and certain other conditions in the head, neck and upper spine. In August 2001, we received FDA clearance for the treatment of tumors anywhere in the body where radiation treatment is indicated. In September 2002, we received a CE mark for the sale of the CyberKnife system in Europe. We received approval for full-body treatment in Japan in June 2008; previously our CyberKnife regulatory approvals in Japan were limited to treatment for indications in the head and neck. The CyberKnife system has also been approved for various indications in Korea, Taiwan, China and other countries. Our customers have reported that over 50,000 patients worldwide have been treated with the CyberKnife system since its commercial introduction.
In the United States, we sell to customers, including hospitals and stand-alone treatment facilities, directly through our sales organization. Outside the United States, we sell to customers in over 75 countries directly and through distributors. We have sales and service offices in Paris, France, Hong Kong, China, Tokyo, Japan, Madrid, Spain, New Delhi, India, Singapore, Moscow, Russia and Munich, Germany. As of December 31, 2008, we had 57 sales personnel in our sales organization.
Our CyberKnife systems are either sold to our customers or placed with our customers pursuant to our shared ownership program. As of December 31, 2008, we had 155 CyberKnife systems installed at customer sites, including 152 sold and three pursuant to our shared ownership program. Of the 155 systems sold and installed, 101 are in the Americas, 21 are in Japan, 19 are in Asia and 14 are in Europe.
Under our shared ownership program, we retain title to the CyberKnife system while the customer has use of the system. Our shared ownership contracts generally require a minimum monthly payment from the customer, and we may earn additional revenue through the use of the system at the site. Generally, minimum monthly payments are equivalent to the revenue generated from treating three to four patients per month, and any revenue received from additional patients is shared between us and the customer. We expect to continue to offer our shared ownership program to new customers and expect the number of installed units pursuant to and revenue from our shared ownership program to decrease in future periods as a percentage of total revenue as we recognize more revenue from CyberKnife systems sold to customers.
The shared ownership program typically has a term of five years, during which the customer has the option to purchase the system at pre-determined prices. At December 31, 2008, we had three systems installed under our shared ownership program. Included in products revenue for the six months ended December 31, 2007 is the sale of two CyberKnife system units that had been in our shared ownership programs by an independent third party for $3.4 million and the sale of a CyberKnife system unit that had been in our shared ownership programs by a former shared ownership program customer for $3.1 million. No revenue was recognized in our condensed consolidated statement of operations for purchases of shared ownership CyberKnife systems during the three and six
22
months ended December 31, 2008.
We manufacture and assemble our CyberKnife systems at our manufacturing facility in Sunnyvale, California. We purchase major components, including the robotic manipulator, the treatment table or robotic couch, the magnetron, which creates the microwaves for use in the linear accelerator, the imaging cameras and the computers, from outside suppliers, some of which are single source. Our reliance on single source suppliers could harm our ability to meet demand for our products in a timely and cost effective manner. However, in most cases, if a supplier were unable to deliver these components, we believe that we would be able to find other sources for these components subject to any regulatory qualifications, if required. We manufacture certain other electronic and electrical subsystems, including the linear accelerator. We then assemble and integrate these components with our proprietary software and perform testing prior to shipment to customer sites.
We generate revenue by selling the CyberKnife system and by providing ongoing services and upgrades to customers following installation of the CyberKnife system. The current U.S. list price for the CyberKnife system ranges from approximately $4.2 million to $5.75 million depending upon system configuration and options purchased by the customer. We also offer optional hardware and software, technical enhancements and upgrades to the CyberKnife system, as part of our multiyear service plans. Currently, our most comprehensive service plan is our Diamond Elite multiyear service plan, or Diamond plan. Under our Diamond plan, customers are eligible to receive up to two upgrades per year, when and if available. Effective July 1, 2008, the Diamond plan lists for $495,000 per year and provides for annual renewals for five years including the one-year warranty period. The customer may cancel the service plan at any time. As of December 31, 2008, 123 of our customers had purchased service plans. Prior to introducing our Diamond plan, we offered legacy service plans, some of which continue to have future upgrade obligations. In these cases, revenue, including CyberKnife product revenue, is recognized ratably over the remaining life of the contract once all upgrade obligations have been satisfied.
The CyberKnife procedure is currently covered and reimbursed by Medicare and other governmental and non-governmental third-party payors. Medicare coverage currently exists in the hospital outpatient setting and in the free-standing clinic setting. For 2008, the Centers for Medicare and Medicaid Services, or CMS, issued a final rule adjusting the reimbursement rates for treatments using our technology in the hospital outpatient department. Under the finalized Medicare payment rules for the hospital outpatient setting, the national payment rates for procedures billed using Medicare billing codes for treatments using the CyberKnife system were $3,930 for the first treatment and $2,871 for each treatment thereafter, up to a maximum of five treatments, which is approximately one percent more than 2007 payment rates. On October 30, 2008, CMS issued final payment rates under these billing codes for 2009. For the calendar year 2009, CMS published slightly decreased payment rates as compared to 2008. The final payment rate under Healthcare Common Procedure Coding System, or HCPCS, code G0339, the billing code for the first treatment, for 2009 is $3,803 and the final payment rate under code G0340, the billing code for each treatment thereafter, for 2009 is $2,580, approximately three and 10 percent less than 2008 payment rates, respectively. Payment for the free-standing clinic setting is governed by the final Medicare Physician Fee Schedule. For 2008 and 2009, payment for HCPCS codes G0339 and G0340 in the freestanding clinic settings for first and subsequent treatments were set by the local Medicare carrier and rates may vary from no payment to a payment rate exceeding the hospital outpatient payment rates. We do not anticipate a significant impact of this rule on our business or results of operations.
In addition to Medicare reimbursement to hospitals and clinics, physicians receive reimbursement for their professional services in the hospital outpatient setting and the free-standing clinic setting. Payment to physicians is based on the Medicare Physician Fee Schedule, and payment amounts are updated on an annual basis. For 2009, the American Medical Association, or AMA, issued guidance that deleted Current Procedural Technology, or CPT, code 61793, the Category I CPT code describing physician work delivering radiosurgery services, and issued the following new CPT codes: 61796, 61797, 61798, 61799, 61800, 63620 and 63621, all relating to neurosurgical procedures that should be used for intracranial and spinal procedures only. Medicare and third-party payors will require the use these new CPT codes to describe physician services for radiosurgery services using our technology for cranial and spinal procedures. Radiosurgery procedures in other anatomies require physicians to bill unlisted CPT codes with no assigned payment rates. Payment rates for unlisted codes are set by the local Medicare carrier and rates may vary from no payment to rates equivalent to the comparable CPT rates for the 61796 series of CPT codes. The inability of physicians to obtain reimbursement under the new CPT codes or any related unlisted or successor CPT codes could result in a material adverse effect on our business.
Our total net revenue was $57.6 million and $52.0 million for the three months ended December 31, 2008 and 2007, respectively, and $113.5 million and $100.7 million for the six months ended December 31, 2008 and 2007, respectively. Our net income (loss) was $1.4 million and $2.3 million for the three months ended December 31, 2008 and 2007, respectively, and ($1.8 million) and $4.6 million for the six months ended December 31, 2008 and 2007, respectively. Our net cash used in operating activities was $12.7 million and $15.2 million during the six months ended December 31, 2008 and 2007, respectively. As of December 31, 2008, our backlog (as further discussed under Backlog below) was approximately $597.9 million. The contingent portion of backlog was $146.2 at December 31, 2008. Contingent backlog consists of backlog associated with contracts that are subject to the satisfaction of contingencies prior to the customer becoming legally bound to proceed with the acquisition of a CyberKnife system. The non-contingent portion of backlog was $451.7 million at December 31, 2008.
23
Our future success will depend in large part on our ability to establish and maintain a competitive position in the market. To compete successfully, we will need to continue to demonstrate the advantages of our products and technologies over alternative procedures, products and technologies, and convince physicians and other healthcare decision makers of the advantages of our products and technologies. Our business and sales and installation cycle does not immediately create recognizable revenue. As such, we must invest in sales activities typically for up to 24 months prior to realizing the revenue from those activities. Our ability to achieve and maintain long-term profitability is largely dependent on our ability to successfully market and sell the CyberKnife system and to control our costs and effectively manage our growth.
Material Weakness in Internal Controls
Previously Reported Material Weaknesses
Material Weakness Identified During the Year Ended June 30, 2008
In connection with our evaluation of internal controls over financial reporting for the fiscal year ended June 30, 2008, we identified a material weakness relating to accounting for revenue transactions.
During the six months ended December 31, 2008, our efforts to remediate the previously reported material weakness in our internal controls over financial reporting related to accounting for revenue transactions consisted of the following corrective actions:
· assessing existing and hiring additional qualified individuals in the finance and accounting organizations;
· strengthening our processes and procedures related to complex revenue recognition transactions; and
· providing additional training for both finance and non-finance personnel involved with our revenue transactions.
However, even after these corrective actions are implemented, the effectiveness of our controls and procedures may be limited by a variety of risks. We are still evaluating the design of these new procedures. Once placed in operation for a sufficient period of time, we will subject them to appropriate tests, in order to determine whether they are operating effectively.
Material Weakness Identified During the Quarter Ended September 30, 2008
In connection with an investigation of allegations made by a former employee regarding possible improprieties in handling and accounting for certain inventory items with respect to the quarter ended September 30, 2008, the Audit Committee of our Board of Directors and management identified a material weakness in our internal control over financial reporting with respect to inventory processes and procedures due to a combination of inadequate communication, record retention, systems, and reporting procedures.
During the three months ended December 31, 2008, our efforts to remediate the previously reported material weakness in our internal controls over financial reporting related to handling and accounting for certain inventory items consisted of the following corrective actions:
· revise certain processes and procedures for inventory handling, the reporting of inventory transactions, and record retention of inventory documentation;
· improve electronic systems for inventory management to more efficiently and timely execute and record inventory handling, which systems should interact with our financial reporting systems;
· improve the training of our employees as it relates to inventory handling and the relationship to financial reporting requirements, as well as the importance of record retention and adhering to established processes; and
· review of qualifications and assessment of the Companys needs with respect to personnel in areas related to inventory, and make appropriate personnel changes and increase supervision and training to effectuate the foregoing changes.
However, even after these corrective actions are implemented, the effectiveness of our controls and procedures may be limited by a variety of risks. We are still evaluating the design of these new procedures. Once placed in operation for a sufficient period of time, we will subject them to appropriate tests, in order to determine whether they are operating effectively.
Although we have taken measures to remediate the previously reported material weaknesses mentioned above, as well as other significant deficiencies and control deficiencies, we cannot assure you that we have identified all, or that we will not in the future have additional material weaknesses, significant deficiencies and control deficiencies.
24
Financial Condition
Sales and Installation Cycle
The CyberKnife system has a relatively long sales and installation cycle because it is a major capital item and requires the approval of senior management at purchasing institutions. The typical sales and installation cycle is up to 24 months in duration and involves multiple steps. Initial steps may include pre-selling activity followed by sales presentations and other sales related activities. After the customer has expressed an intention to purchase a CyberKnife system, we typically negotiate and enter into a terms agreement setting forth the business and economic terms for the sale or acquisition of the CyberKnife system and multiyear service plan. After execution of a terms agreement, the customer typically has a specified window in which to complete final negotiation of legal terms for the acquisition of the CyberKnife system. We bifurcated the process of negotiating agreements on business and legal terms in order to reduce the level of sales force involvement in negotiation of legal terms and improve the efficiency of our customer contracting process. Nevertheless, many customers, particularly in international markets, opt to negotiate a full purchase agreement at the time of sale. The last step in the sales and installation cycle is installation of the CyberKnife system. Prior to installation, a purchasing institution must typically obtain a radiation device installation permit, and in some cases, a certificate of need, or CON, both of which must be granted by state and local government bodies. Recently, as a result of healthcare cost considerations and sensitivity to the cost of major capital equipment items, some state CON boards have become more conservative in the evaluation of CON applications. This trend, if it continues, may make the CON process more protracted and uncertain. In addition, the purchasing institution must build a radiation shielded facility or upgrade an existing facility to house the CyberKnife system. We typically receive a deposit at the time the terms agreement or full purchase agreement is entered into, or shortly thereafter, and the remaining balance for the sale of the CyberKnife system upon delivery and installation. The customer also typically selects a service plan at the time of signing a CyberKnife system terms agreement and enters into the service plan agreement prior to installation of the system.
Upon installation, we typically recognize the CyberKnife system sale price less the fair value of one year of service. We recognize the fair value of the first year of service as revenue pro rata over the twelve months following installation. In addition, if the customer has purchased our Diamond plan and assuming annual renewals, we would receive payment at the beginning of each of the second, third and fourth years of the multiyear service plan and recognize that revenue pro rata over each year.
Legacy Service Plans
Prior to introducing our Diamond plan, we offered our Platinum Elite multiyear service plan, or Platinum plan. This legacy service plan was structured so that we have an obligation to deliver two upgrades per year over the course of the multiyear service plan. If we fail to deliver the upgrades, our customers are entitled to receive a refund of up to $100,000 for each upgrade not offered. Beginning in November 2005, we phased out offering these legacy service plans to new customers.
The Platinum plan obligates us to deliver two upgrades per year during the term of the contract. We have not established fair value for those future obligations; hence, generally accepted accounting principles in the United States, or GAAP, requires that we cannot begin to recognize any of the revenue derived from the sale of the CyberKnife system or the associated service plans until all upgrade obligations have been fulfilled. Therefore, the payments made by our customers who have our legacy Platinum plan are categorized as deferred revenue and are recognized as revenue after we fulfill all obligations to deliver upgrades. Once we fulfill all upgrade obligations with respect to a specific Platinum plan, we ratably recognize the revenue from the sale of the CyberKnife system and the Platinum plan over the remaining life of the contract.
Upgrades
Customers may purchase additional upgrades as optional extras prior to the delivery of all originally specified upgrade obligations. Such additional upgrades are considered elements of the original arrangement and associated revenues are deferred until the earlier of: (1) delivery of all elements, or (2) establishment of vendor specific objective evidence, or VSOE, of fair value for all undelivered elements. Sales of additional upgrades after delivery of all specified upgrade obligations, as stated in the original contract, are considered separate arrangements and are recognized once all revenue recognition criteria applicable to the separate arrangements are met.
Warranty
All customers purchasing a CyberKnife system receive a one-year warranty. In circumstances where we have VSOE of fair value for all undelivered elements, we recognize the CyberKnife system purchase price minus the fair value of one year of support upon installation, and we recognize the value of one year of support ratably over the twelve months following installation.
Shared Ownership Program Revenue
As of December 31, 2008, our shared ownership program involved U.S. sites only. We recognize revenue monthly from our shared ownership program that consists of a minimum monthly payment. We also recognize usage-based revenue in excess of the monthly minimum based on usage reports from our customers. We recognized revenue from shared ownership programs of $876,000 and $1.9 million for the three and six months ended December 31, 2008, respectively, and $3.0 million and $5.4 million for the three and six months ended December 31, 2007, respectively. In limited cases, we received nonrefundable upfront payments from shared ownership program customers which are treated as deferred revenue and recognized over the term of the contract.
25
The CyberKnife system shared ownership systems are recorded within property and equipment and are depreciated over their estimated life of ten years. Depreciation and warranty expense attributable to shared ownership systems are recorded within cost of shared ownership program as they are incurred.
Japan Customized Service Revenue
In May and December 2003, we entered into separate contractual arrangements to deliver customized services to our distributor in Japan for 22 CyberKnife systems previously sold. These customized services consist of two upgrade levels and are being delivered over an extended period concurrent with the distributors efforts to coordinate delivery with its end user customers. The obligations under the upgrade programs for these 22 systems were completed as of September 30, 2008. We do not plan to offer this customized service program in the future and instead expect to offer our standard multiyear service plans.
International Sales Revenue
For international sales, we recognize revenue once we have met all of our obligations associated with the sale agreement, other than for undelivered service elements for which we have VSOE of fair value. In most cases, this occurs after the distributor has shipped the unit to the end user, assuming all other obligations have been satisfied. Payments are sometimes secured through letters of credit. In situations where we are directly responsible for installation, we recognize revenue once we have installed the CyberKnife system and have confirmed performance against specification.
In situations with legacy plans where we have future obligations related to software upgrades that are subject to potential refunds, we defer revenue from the sale and service of the CyberKnife system until the final upgrade has been delivered and accepted. After we have delivered all upgrades associated with a service plan and thus eliminated any contractual right to a refund, we ratably recognize the revenue from the sale of the CyberKnife system and the plan over the remaining life of the contract or until we have VSOE of the fair value of remaining undelivered elements. Net revenue from international customers was $22.1 million and $35.7 million for the three and six months ended December 31, 2008, respectively, compared to $20.3 million and $39.1 million for the three and six months ended December 31, 2007.
Backlog
Backlog consists of the sum of deferred revenue, future payments that our customers are contractually committed to make and signed contingent and non-contingent contracts that we believe have a substantially high probability of being booked as revenue from CyberKnife system sale agreements, service plans and minimum payment requirements associated with our shared ownership program. Contingencies associated with contingent contracts that are included within backlog may include state or local government approval of a certificate of need for the installation of a radiosurgery system, approval by the board of directors of the hospital or other purchaser of the system and establishment of financing and formation of legal entities by purchasers of systems and, in the case of terms agreements, final negotiation and agreement upon our legal terms for the purchase or acquisition of the CyberKnife system. In addition, in some cases in which customers negotiate full purchase agreements, these agreements are also subject to certain contingencies. We review, on a quarterly basis with respect to each contingent contract included in backlog, whether customer engagement and progress toward satisfaction of contingencies warrant continued inclusion of the contract within backlog.
As of December 31, 2008, our backlog, as defined above, was approximately $597.9 million, compared to backlog of approximately $647.0 million as of June 30, 2008. Of the total backlog, $311.1 million represented CyberKnife system sales, as compared to $358.6 million as of June 30, 2008, and $286.8 million represented revenue from service plans and other recurring revenues, as compared to $288.4 million as of June 30, 2008. The contingent portion of backlog was $146.2 million at December 31, 2008, as compared to $187.3 million at June 30, 2008. Contingent backlog consists of backlog under contracts that are subject to the satisfaction of contingencies prior to the customer becoming legally bound to proceed with the acquisition of a CyberKnife system. The non-contingent portion of backlog was $451.7 million at December 31, 2008, as compared to $459.7 million at June 30, 2008. We anticipate that this backlog will be recognized over the next five years as installations occur, upgrades are delivered and services are provided. Although backlog includes contractual commitments from our customers, we may be unable to convert this entire backlog, including the entire non-contingent backlog, into recognized revenue due to factors outside our control.
Results of Operations
Overview
Our results of operations are divided into the following components:
Net revenue. Our net revenue consists primarily of product revenue (revenue derived primarily from the sale of CyberKnife systems and the sale of linacs for other uses), shared ownership program revenue (revenue generated from our shared ownership program), services revenue (revenue generated from sales of service plans and training) and other revenue (revenue from specialized upgrade services for units previously sold in Japan and other specialized services).
26
Cost of revenue. Cost of revenue consists primarily of material, labor and overhead costs. In future periods we expect cost of revenue to decrease as a percentage of total net revenue due to anticipated higher-margin product sales and increased absorption of manufacturing overhead costs associated with increased production volumes, improved efficiencies for supplies and materials and improved labor and manufacturing efficiencies. In addition, we expect to record restructuring-related charges throughout the remainder of the fiscal year ended June 30, 2009 and expect to realize cost savings as a result of the Workforce Alignment Plan (the Plan) beginning in the fiscal year ended June 30, 2010.
Selling and marketing expenses. Selling and marketing expenses consist primarily of costs for personnel and costs associated with participation in medical conferences, physician symposia, and advertising and promotional activities. We expect to record restructuring-related charges throughout the remainder of the fiscal year ended June 30, 2009 and expect to realize cost savings as a result of the Plan beginning in the fiscal year ended June 30, 2010. Marketing expenses may fluctuate from quarter to quarter due to the timing of major marketing events, such as significant trade shows.
Research and development expenses. Research and development expenses consist primarily of activities associated with our product development, regulatory, and clinical study arrangements. In future periods, we expect research and development expenses to grow in absolute terms as we continue our investment in new technologies, enhancements to the CyberKnife system, increased clinical studies, and as we increase headcount and development activities. Our objective is to manage growth in these expenditures such that they will decrease as a percentage of total net revenue as we leverage our existing infrastructure and realize economies of scale. In addition, we expect to record restructuring-related charges throughout the remainder of the fiscal year ended June 30, 2009 and expect to realize cost savings as a result of the Plan beginning in the fiscal year ended June 30, 2010.
General and administrative expenses. General and administrative expenses consist primarily of compensation and related costs for finance, legal, and human resources, and external expenses related to accounting, legal and other consulting fees. In future periods, we expect general and administrative expenses to grow in absolute terms as we incur additional costs related to the overall growth of our business, but to decrease as a percentage of total net revenue as we leverage our existing infrastructure and realize economies of scale. We expect to record restructuring-related charges throughout the remainder of the fiscal year ended June 30, 2009 and expect to realize cost savings as a result of the plan beginning in the fiscal year ended June 30, 2010.
Other income, net. Other income, net consists primarily of unrealized losses on our long-term trading securities, net of unrealized gains on our put option, interest earned on our cash and cash equivalents and investments, foreign currency transaction gains and losses, and state and local sales and use tax fines and penalties. We expect interest income to decrease in the near future in response to the recent decline in interest rates.
Deferred RevenueLegacy Multiyear Service Plans
We are required to defer all of the revenue associated with our legacy multiyear service plans, including our Platinum and Gold service plans, until we have satisfied all of the specified obligations related to the delivery of upgrades to the CyberKnife system during the life of the service plan. This includes deferring the cash received for the purchase of the CyberKnife system and multiyear service plans until we have delivered all upgrades which the customer is eligible to receive. Once we have satisfied our obligations for delivery of upgrades under the plans, we recognize revenue ratably over the remaining life of the service plan. We have not offered these legacy multiyear service plans to new customers since we phased them out when we introduced our Diamond plan in November 2005, but continue to provide service for 38 legacy plans as of December 31, 2008. Therefore, our deferred revenue has been higher in certain periods where we have installed more units with legacy contracts, and it should decrease in future periods as we satisfy the contractual obligations and recognize the revenue associated with those installed units. However, we do not anticipate receiving significant incremental cash flow from operations related to these legacy contracts.
Three Months Ended December 31, 2008 Compared to Three Months Ended December 31, 2007
Net revenue
|
|
Three Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(in thousands) |
|
||||
Net revenue |
|
$ |
57,637 |
|
$ |
52,038 |
|
Products |
|
$ |
41,301 |
|
$ |
39,131 |
|
Shared ownership program |
|
$ |
876 |
|
$ |
3,044 |
|
Services |
|
$ |
13,922 |
|
$ |
8,950 |
|
Other |
|
$ |
1,538 |
|
$ |
913 |
|
Total net revenue for the three months ended December 31, 2008 increased $5.6 million from the three months ended December 31, 2007. During the three months ended December 31, 2008, 10 CyberKnife system units were installed and one unit was sold to a distributor, all of which were sold and none of which were attributable to our shared ownership program, compared to 12
27
units installed, including 11 units sold and one attributable to our shared ownership program in the three months ended December 31, 2007. In accordance with our revenue recognition policy and the terms of our service plans, we recognized revenue associated with the sale of 11 CyberKnife system units for the three months ended December 31, 2008, compared to 14 CyberKnife system units for the three months ended December 31, 2007.
Product revenue for the three months ended December 31, 2008 increased $2.2 million from the three months ended December 31, 2007. In accordance with our revenue recognition policy and the terms of our service plans, we recognized revenue associated with the sale of 11 CyberKnife system units for the three months ended December 31, 2008, compared to 14 CyberKnife system units for the three months ended December 31, 2007. Of the 14 CyberKnife system units sold, we satisfied all revenue recognition criteria for three units previously sold to a distributor in China and recognized $5.6 million of products revenue related to these units during the three months ended December 31, 2007. Also included in products revenue during the three months ended December 31, 2007, is $3.4 million related to the purchase by a third party of two of our CyberKnife system units that had been in our shared ownership programs. Though the number of system units sold and recognized decreased during the three months ended December 31, 2008, product revenue increased due to an increase in the average unit selling price and an increase in sales of additional system upgrades. In addition, we recognize product revenue ratably over the remaining lives of the service plans for those legacy multiyear service plans where we have satisfied our upgrade delivery obligations. During the three months ended December 31, 2008 and 2007, we recognized product revenue attributable to these legacy multiyear plans for 19 units and 14 units, respectively.
Service revenue for the three months ended December 31, 2008 increased approximately $5.0 million from the three months ended December 31, 2007, primarily attributable to an increase in the number of customer sites under service plans. As of December 31, 2008 and 2007, 123 and 86 of our customers had purchased service plans, respectively. Shared ownership program revenue for the three months ended December 31, 2008 decreased approximately $2.2 million from the three months ended December 31, 2007. Subsequent to December 31, 2007, we sold 9 units that were formerly a part of our shared ownership program. We anticipate revenue from our shared ownership program will continue to decrease in future periods due to the sale during fiscal 2008 of such units. Other revenue for the three months ended December 31, 2008, increased approximately $625,000 from the three months ended December 31, 2007, primarily attributable to $1.0 million of revenue recognized during the three months ended December 31, 2008 for a long-term manufacturing contract partially offset by a decrease in revenue from upgrade services in Japan, classified as Other revenue in our condensed consolidated statements of operations for the three months ended December 31, 2008, due to a decrease in upgrade services provided to our installed systems in Japan.
Gross profit
|
|
Three Months Ended December 31, |
|
||||||||
|
|
2008 |
|
2007 |
|
||||||
|
|
(Dollars in |
|
(% of
net |
|
(Dollars in |
|
(% of
net |
|
||
Gross profit |
|
$ |
29,409 |
|
51.0 |
% |
$ |
27,862 |
|
53.5 |
% |
Products |
|
$ |
23,781 |
|
57.6 |
% |
$ |
22,650 |
|
57.9 |
% |
Shared ownership program |
|
$ |
669 |
|
76.4 |
% |
$ |
2,284 |
|
75.0 |
% |
Services |
|
$ |
4,950 |
|
35.6 |
% |
$ |
2,559 |
|
28.6 |
% |
Other |
|
$ |
9 |
|
0.6 |
% |
$ |
369 |
|
40.4 |
% |
The decrease in gross profit as a percentage of revenue was due primarily to a significant increase in services revenue as a percentage of total net revenues, which have higher costs of revenue as compared to product revenue, plus a decrease in shared ownership revenues, which have lower costs of revenue as compared to product revenue.
Selling and marketing expenses
|
|
Three Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
Sales and marketing |
|
$ |
10,723 |
|
$ |
11,167 |
|
% of net revenue |
|
18.6 |
% |
21.5 |
% |
||
Selling and marketing expenses for the three months ended December 31, 2008 decreased $444,000 from the three months ended December 31, 2007. The decrease was primarily attributable to a decrease of $1.4 million in trade show expenses related to the timing of the American Society for Therapeutic Radiology and Oncology, or ASTRO, trade show, which was held during the first quarter of fiscal year 2009 but was held during the second quarter of fiscal year 2008, partially offset by an increase of $183,000 in salaries and related costs largely due to increased headcount, an increase in sales commissions of $371,000 due to increased commissions earned during the three months ended December 31, 2008, and an increase of $365,000 in consulting and outside service expenses mainly due to increased consulting activity for lobbying. As a percentage of net revenue, selling and marketing expenses
28
for the three months ended December 31, 2008 decreased to 18.6% as compared to 21.5% for the three months ended December 31, 2007.
Research and development expenses
|
|
Three Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
Research and development |
|
$ |
8,794 |
|
$ |
8,128 |
|
% of net revenue |
|
15.3 |
% |
15.6 |
% |
||
Research and development expenses for the three months ended December 31, 2008 increased $666,000 from the three months ended December 31, 2007. The increase was primarily attributable to an increase of $596,000 in salary and related costs largely due to increased headcount. Research and development expenses as a percentage of net revenue was consistent for the three months ended December 31, 2008 and 2007 at 15.3% and 15.6%, respectively.
General and administrative expenses
|
|
Three Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
General and administrative |
|
$ |
9,259 |
|
$ |
7,976 |
|
% of net revenue |
|
16.1 |
% |
15.3 |
% |
||
General and administrative expenses for the three months ended December 31, 2008 increased $1.3 million from the three months ended December 31, 2007. The increase was primarily attributable to an increase of $680,000 in salary and related costs primarily due to increased headcount and an increase of $511,000 in legal fees and accounting, audit and tax expenses as a result of the investigation of the handling and accounting for certain inventory items conducted during the three months ended December 31, 2008. As a percentage of total net revenue, general and administrative expenses for the three months ended December 31, 2008 increased to 16.1% as compared to 15.3% for the three months ended December 31, 2007.
Other income, net
|
|
Three Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
Other income, net |
|
$ |
748 |
|
$ |
2,197 |
|
% of net revenue |
|
1.3 |
% |
4.2 |
% |
||
Other income, net decreased $1.4 million for the three months ended December 31, 2008 from the three months ended December 31, 2007. In November 2008, the Company entered into an agreement (Rights Agreement) with UBS, the financial institution broker, which provides the Company with ARS Rights (Rights) to sell its ARS at par value to UBS at any time during the period June 30, 2010 through July 2, 2012. These Rights are a separate freestanding instrument accounted for separately from the ARS, and are registered, nontransferable securities accounted for as a put option initially recorded at fair value. Due to the Company entering into this Rights Agreement with UBS and enabling UBS to sell the ARS at any time, the ARS previously reported as available-for-sale have been transferred to trading securities and are classified as long-term trading securities on the condensed consolidated balance sheet as of December 31, 2008. Due to the change in classification to trading securities at the time of entering into the Rights Agreement, we transferred the previously accumulated unrealized loss on these ARS of $3.8 million from Accumulated other comprehensive income (loss) to Other income, net and recorded an additional unrealized loss of $407,000 in Other income, net relating to the change in fair value of the trading securities from November 2008 through the end of the reporting period for a total unrealized loss of $4.2 million included in net income for the three months ended December 31, 2008. The total loss of $4.2 million was partially offset by a $3.3 million gain recognized on the put option, for a net loss of $860,000 included in Other income, net. The decrease is also attributable to a $1.2 million decrease in interest income due to a decrease in both the average daily balances kept in interest bearing accounts and the interest rates earned on amounts kept in those accounts during the three months ended December 31, 2008 compared to the three months ended December 31, 2007, partially offset by a $607,000 increase in foreign currency transaction gains due to higher net asset balances in Euro-denominated accounts. As a percentage of total net revenue, other income, net for the three months ended December 31, 2008 decreased to 1.3% as compared to 4.2% for the three months ended December 31, 2007.
29
Provision for income taxes
|
|
Three Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
Provision for income taxes |
|
$ |
31 |
|
$ |
445 |
|
% of net revenue |
|
0.1 |
% |
0.9 |
% |
||
On a quarterly basis, we provide for income taxes based upon an estimated annual effective income tax rate. This process involves estimating actual current tax expense together with assessing temporary differences in the treatment of items for tax purposes versus financial accounting purposes that may create net deferred tax assets and liabilities.
For the three months ended December 31, 2008, we recorded income tax expense of $31,000, as compared to income tax expense of $445,000 for the three months ended December 31, 2007. The provision is related primarily to foreign subsidiaries. The decrease in income tax of $414,000 is primarily due to a decrease in corporate earnings of foreign subsidiaries during the quarter.
Six Months Ended December 31, 2008 Compared to Six Months Ended December 31, 2007
Net revenue
|
|
Six Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(in thousands) |
|
||||
Net revenue |
|
$ |
113,494 |
|
$ |
100,684 |
|
Products |
|
$ |
78,756 |
|
$ |
76,115 |
|
Shared ownership program |
|
$ |
1,912 |
|
$ |
5,356 |
|
Services |
|
$ |
29,829 |
|
$ |
15,949 |
|
Other |
|
$ |
2,997 |
|
$ |
3,264 |
|
Total net revenue for the six months ended December 31, 2008 increased $12.8 million from the six months ended December 31, 2007. During the six months ended December 31, 2008, 15 CyberKnife system units were installed and one unit was sold to a distributor, all of which were sold and none of which were attributable to our shared ownership program, compared to 17 units installed, including 15 units sold and two attributable to our shared ownership program in the six months ended December 31, 2007. In accordance with our revenue recognition policy and the terms of our service plans, we recognized revenue associated with the sale of 18 CyberKnife system units for the six months ended December 31, 2008, compared to 25 CyberKnife system units for the six months ended December 31, 2007.
Product revenue for the six months ended December 31, 2008 increased $2.6 million from the six months ended December 31, 2007. In accordance with our revenue recognition policy and the terms of our service plans, we recognized revenue associated with the sale of 18 CyberKnife system units for the six months ended December 31, 2008, compared to 25 CyberKnife system units for the six months ended December 31, 2007. Though the number of system units sold and recognized decreased during the six months ended December 31, 2008, product revenue increased primarily due to an increase in average unit selling price and the fulfillment of final upgrade delivery obligations at the end of the service contracts for two units under our legacy multiyear service plans, which allowed us to recognize product revenue in full of $5.4 million. During the six months ended December 31, 2008, we satisfied all revenue recognition criteria for seven units (included in the 25 CyberKnife system units sold) previously sold to a distributor in China during the six months ended December 31, 2007 and recognized $13.1 million of products revenue related to these units. Also included in products revenue for the six months ended December 31, 2007 was the sale of three CyberKnife system units that had been in our shared ownership programs for $6.5 million. In addition, we recognize product revenue ratably over the remaining lives of the service plans for those legacy multiyear service plans where we have satisfied our upgrade delivery obligations. During the six months ended December 31, 2008 and 2007, we recognized product revenue attributable to these legacy multiyear plans for 21 units and 14 units, respectively.
Service revenue for the six months ended December 31, 2008 increased approximately $13.9 million from the six months ended December 31, 2007, primarily attributable to an increase in the number of customer sites under service plans. As of December 31, 2008 and 2007, 123 and 86 of our customers had purchased service plans, respectively. In addition, revenue for two platinum sites was recognized in full during the six months ended December 31, 2008, as the final upgrades were installed at these sites at the end of their service contracts. Shared ownership program revenue for the six months ended December 31, 2008 decreased approximately $3.4 million from the six months ended December 31, 2007. Subsequent to December 31, 2007, we sold 9 units that were formerly a part
30
of our shared ownership program. We anticipate revenue from our shared ownership program will continue to decrease in future periods due to the sale during fiscal 2008 of such units. Revenue from upgrade services in Japan, classified as Other revenue in our consolidated statements of operations for the six months ended December 31, 2008, decreased approximately $267,000 from the six months ended December 31, 2007 due to a decrease in upgrade services provided to our installed systems in Japan.
Gross profit
|
|
Six Months Ended December 31, |
|
||||||||
|
|
2008 |
|
2007 |
|
||||||
|
|
(Dollars in |
|
(% of net |
|
(Dollars in |
|
(% of net |
|
||
Gross profit |
|
$ |
57,838 |
|
51.0 |
% |
$ |
53,773 |
|
53.4 |
% |
Products |
|
46,492 |
|
59.0 |
% |
43,194 |
|
56.7 |
% |
||
Shared ownership program |
|
1,443 |
|
75.5 |
% |
3,884 |
|
72.5 |
% |
||
Services |
|
9,672 |
|
32.4 |
% |
5,100 |
|
32.0 |
% |
||
Other |
|
231 |
|
7.7 |
% |
1,595 |
|
48.9 |
% |
||
The decrease in gross profit as a percentage of net revenue was due primarily to a significant increase in services revenue as a percentage of total net revenues, which have higher costs of revenue as compared to product revenue, plus a decrease in shared ownership revenues, which have lower costs of revenue as compared to product revenue. In addition, charges for slow-moving and obsolete parts in the six months ended December 31, 2008 increased $1.1 million compared to the six months ended December 31, 2007.
Selling and marketing expenses
|
|
Six Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
Sales and marketing |
|
$ |
24,203 |
|
$ |
21,323 |
|
% of net revenue |
|
21.3 |
% |
21.2 |
% |
||
Selling and marketing expenses for the six months ended December 31, 2008 increased $2.9 million from the six months ended December 31, 2007. The increase was primarily attributable to an increase of $829,000 in salaries largely due to increased headcount, an increase of $897,000 in sales commissions due to previously paid amounts that were expensed for employees terminating during the six months ended December 31, 2008, and an increase of $519,000 in travel expenses as a result of increasing our international sales presence. Selling and marketing expenses as a percentage of net revenue was consistent for the six months ended December 31, 2008 and 2007 at 21.3% and 21.2%, respectively.
Research and development expenses
|
|
Six Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
Research and development |
|
$ |
17,548 |
|
$ |
15,843 |
|
% of net revenue |
|
15.5 |
% |
15.7 |
% |
||
Research and development expenses for the six months ended December 31, 2008 increased $1.7 million from the six months ended December 31, 2007. The increase was primarily attributable to an increase of $1.9 million in salary and related costs largely due to increased headcount and an increase of $249,000 in business promotion and support group expenses related to new lung and prostate cancer studies, partially offset by a decrease of $1.0 million in consulting fee expense due to a decrease in research and development project outsourcing. Research and development expenses as a percentage of net revenue was consistent for the six months ended December 31, 2008 and 2007 at 15.5% and 15.7%, respectively.
General and administrative expenses
|
|
Six Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
General and administrative |
|
$ |
19,692 |
|
$ |
15,877 |
|
% of net revenue |
|
17.4 |
% |
15.8 |
% |
||
General and administrative expenses for the six months ended December 31, 2008 increased $3.8 million from the six months ended December 31, 2007. The increase was primarily attributable to $2.0 million of non-recurring employee separation costs and an increase of $1.4 million in salary and related costs primarily due to increased headcount. As a percentage of total net revenue, general
31
and administrative expenses for the six months ended December 31, 2008 increased to 17.4% as compared to 15.8% for the six months ended December 31, 2007.
Other income, net
|
|
Six Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
Other income, net |
|
$ |
1,861 |
|
$ |
4,809 |
|
% of net revenue |
|
1.6 |
% |
4.8 |
% |
||
Other income, net decreased $2.9 million for the six months ended December 31, 2008 from the six months ended December 31, 2007. In November 2008, the Company entered into an agreement (Rights Agreement) with UBS, the financial institution broker, which provides the Company with ARS Rights (Rights) to sell its ARS at par value to UBS at any time during the period June 30, 2010 through July 2, 2012. These Rights are a separate freestanding instrument accounted for separately from the ARS, and are registered, nontransferable securities accounted for as a put option initially recorded at fair value. Due to the Company entering into this Rights Agreement with UBS and enabling UBS to sell the ARS at any time, the ARS previously reported as available-for-sale have been transferred to trading securities and are classified as long-term trading securities on the condensed consolidated balance sheet as of December 31, 2008. Due to the change in classification to trading securities at the time of entering into the Rights Agreement, we transferred the previously accumulated unrealized loss on these ARS of $3.8 million from Accumulated other comprehensive income (loss) to Other income, net and recorded an additional unrealized loss of $407,000 in Other income, net, relating to the change in fair value of the trading securities from November 2008 through the end of the reporting period for a total unrealized loss of $4.2 million included in net income for the three and six months ended December 31, 2008. The total loss of $4.2 million was partially offset by a $3.3 million gain recognized on the put option, for a net loss of $860,000 included in Other income, net. The decrease is also attributable to a $2.7 million decrease in interest income due to a decrease in both the average daily balances kept in interest bearing accounts and the interest rates earned on amounts kept in those accounts during the three months ended December 31, 2008 compared to the three months ended December 31, 2007, partially offset by a $581,000 increase in foreign currency transaction gains due to higher net asset balances in Euro-denominated accounts. As a percentage of total net revenue, other income, net for the six months ended December 31, 2008 decreased to 1.6% as compared to 4.8% for the six months ended December 31, 2007.
Provision for income taxes
|
|
Six Months Ended December 31, |
|
||||
|
|
2008 |
|
2007 |
|
||
|
|
(Dollars in thousands) |
|
||||
Provision for income taxes |
|
$ |
85 |
|
$ |
931 |
|
% of net revenue |
|
0.1 |
% |
0.9 |
% |
||
On a quarterly basis, we provide for income taxes based upon an estimated annual effective income tax rate. This process involves estimating actual current tax expense together with assessing temporary differences in the treatment of items for tax purposes versus financial accounting purposes that may create net deferred tax assets and liabilities.
For the six months ended December 31, 2008, we recorded income tax expense of $85,000, as compared to income tax expense of $931,000 for the six months ended December 31, 2007. The provision is related primarily to foreign subsidiaries. The decrease in income tax of $846,000 is primarily due to a decrease in corporate earnings of foreign subsidiaries during the quarter.
Stock-Based Compensation Expense
SFAS 123R requires forfeitures to be estimated at the time of grant and revised, if necessary in subsequent periods if actual forfeitures differ from initial estimates. Stock-based compensation expense was recorded net of estimated forfeitures for the three and six months ended December 31, 2008 and 2007 such that expense was recorded only for those stock-based awards that are expected to vest. For the three and six months ended December 31, 2008, we recorded $3.6 million and $8.6 million, respectively, of stock-based compensation expense, net of estimated forfeitures, for stock options, ESPP options and restricted stock units granted, compared to $4.3 million and $8.6 million for the three and six months ended December 31, 2007, respectively. During the three and six months ended December 31, 2008, we recognized $854,000 and $897,000, respectively, of stock-based compensation expense related to accelerated vesting of stock options and RSUs in conjunction with non-recurring employee separation costs.
As of December 31, 2008, there was approximately $36.7 million, net of forfeitures, of unrecognized compensation cost related to unvested stock options, ESPP options and restricted stock units which we expect to be recognized over a weighted average
32
period of 2.31 years.
Liquidity and Capital Resources
At December 31, 2008, we had $29.4 million in cash and cash equivalents. During the six months ended December 31, 2008, cash and cash equivalents decreased by $7.6 million. This decrease was primarily attributable to cash used in operating activities of $12.7 million, and was partially offset by cash provided by investing activities of $1.4 million and cash provided by financing activities of $3.5 million. In addition, we have a line of credit available that allows for borrowings against our long-term trading securities, as determined by the financial institution broker. We believe that we have sufficient cash resources and anticipated cash flows to continue in operation for at least the next 12 months.
Six Months Ended December 31, 2008 and 2007
Cash Flows From Operating Activities. Net cash used in operating activities for the six months ended December 31, 2008 was $12.7 million. Our net loss for the first six months of fiscal 2009 of $1.8 million was partially offset by an increase in accrued liabilities of $5.2 million. Negative cash flow from working capital changes include an increase in accounts receivable of $7.5 million, a decrease in customer advances of $6.5 million due to a decrease in advanced payments made by customers for product shipments, an increase in inventories of $3.3 million due to an increase in our business volume and a decrease in deferred revenue, net of deferred cost of revenue, of $7.2 million. The increase in accounts receivable was primarily a result of the timing difference between the shipment of products and the receipt of customer payment. The increase in accrued liabilities was primarily due to increases in accrued compensation related to payroll, payroll taxes and non-recurring employee separation expenses as well as increases in accrued sales and use and foreign value-added taxes. The decrease in deferred revenue, net of deferred cost of revenue, was primarily a result of the timing of differences between invoicing customers under service contracts and the recognition of revenue previously deferred for two platinum sites that were fully recognized during the six months ended December 31, 2008, as the final upgrades were installed at these sites during the final quarter of the service contract term. Non-cash charges included $3.3 million of depreciation and amortization expense, $8.6 million of stock-based compensation and $860,000 unrealized loss on auction rate securities as a result of transferring the securities from available-for-sale to trading securities, net of unrealized gains on the put option recorded in connection with the ARS settlement agreement signed with UBS.
Net cash used in operating activities for the six months ended December 31, 2007 was $15.2 million. Our net income for the first six months of fiscal 2008 of $4.6 million was offset by an increase in accounts receivable of $5.1 million, an increase in inventories of $2.1 million, a decrease in accounts payable of $5.1 million, a decrease in accrued liabilities of $4.1 million and a decrease in deferred revenue, net of deferred cost of revenue, of $20.0 million. The increase in accounts receivable was primarily a result of the timing difference between the shipment of products and the receipt of customer payment. The increase in inventory is due to an increase in our business volume. The decrease in accounts payable is a result of the timing of differences between the receipt of vendor invoices and the payment of such invoices. The decrease in accrued liabilities was primarily due to decreased accrued compensation related to commissions, payroll taxes, and bonuses. The decrease in deferred revenue, net of deferred cost of revenue, was primarily a result of the timing of differences between invoicing customers under service contracts and the recognition of revenue over the contractual service period, the continued satisfaction of specified obligations to begin revenue recognition for units covered by our legacy service plans and the recognition of revenue and cost of revenue for units previously shipped to a distributor in China. Positive cash flow from working capital changes include a decrease in prepaid and other current assets of $1.0 million and an increase in customer advances of $2.6 million due to an increase in advanced payments made by customers for product shipments. Non-cash charges included $3.9 million of depreciation and amortization expense and $8.6 million of stock-based compensation.
Cash Flows From Investing Activities. Net cash provided by investing activities was $1.4 million for the six months ended December 31, 2008 and was mainly attributable to a decrease in restricted cash of $4.2 million, partially offset by net marketable security activities of ($1.4) million, which consisted of $76.1 million in purchases partially offset by $74.7 million of sales and maturities. We also used $1.4 million of cash for purchases of property and equipment. Net cash used in investing activities was $3.7 million for the six months ended December 31, 2007 and was primarily attributable to purchases of property and equipment. The purchases of property and equipment were due to the expansion of our facilities and operations in both periods.
Cash Flows From Financing Activities. Net cash provided by financing activities for the six months ended December 31, 2008 was $3.5 million and was entirely attributable to proceeds from the exercise of common stock options and the purchase of common stock under our employee stock plans. Net cash provided by financing activities for the six months ended December 31, 2007 was $1.7 million and was attributable to proceeds from the exercise of common stock options and the purchase of common stock under our employee stock plans of $4.3 million and income tax benefits from employee stock plans of $718,000, offset by stock repurchases of $3.3 million.
Operating Capital and Capital Expenditure Requirements
Our future capital requirements depend on numerous factors. These factors include but are not limited to the following:
· revenue generated by sales of the CyberKnife system, service plans and shared ownership program;
33
· costs associated with our sales and marketing initiatives and manufacturing activities;
· rate of progress and cost of our research and development activities;
· costs of obtaining and maintaining FDA and other regulatory clearances of the CyberKnife system;
· effects of competing technological and market developments; and
· number and timing of acquisitions and other strategic transactions.
We believe that our current cash and cash equivalents, along with the cash we expect to generate from operations, will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least 12 months. If these sources of cash are insufficient to satisfy our liquidity requirements beyond 12 months, we may seek to sell additional equity or debt securities, liquidate our investment holdings or obtain a credit facility. The sale of additional equity or convertible debt securities could result in dilution to our stockholders. If additional funds are raised through the issuance of debt securities, these securities could have rights senior to those associated with our common stock and could contain covenants that would restrict our operations. Additional financing may not be available at all, or in amounts or on terms acceptable to us.
Contractual Obligations and Commitments
There have been no significant changes to the contractual obligations and commitments we reported in our Annual Report on Form 10-K for the year ended June 30, 2008.
Off-Balance Sheet Arrangements
We do not have any significant off-balance sheet arrangements.
Inflation
We do not believe that inflation has had a material impact on our business and operating results during the periods presented.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with US GAAP. The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from those estimates under different assumptions or conditions.
For a description of our critical accounting policies and estimates, please refer to the Critical Accounting Policies and Estimates section of our Managements Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the year ended June 30, 2008, as filed with the U.S. Securities and Exchange Commission. Other than the item discussed below, there have been no material changes in any of our accounting policies since June 30, 2008.
Investments
We account for certain assets in accordance with SFAS 159. In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial LiabilitiesIncluding an amendment of FASB Statement No. 115 (SFAS 159). SFAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value, with changes in fair value recognized in earnings each reporting period. The election, called the fair value option, will enable entities to achieve an offset accounting effect for changes in fair value of certain related assets and liabilities without having to apply complex hedge accounting provisions. In November 2008, we entered into an agreement (Rights Agreement) with UBS, the financial institution broker, which provides us with ARS Rights (Rights) to sell our ARS at par value to UBS at any time during the period June 30, 2010 through July 2, 2012. These Rights are a separate freestanding instrument accounted for separately from the ARS, and are registered, nontransferable securities accounted for as a put option initially recorded at fair value. Under the Rights Agreement, UBS may, at its discretion, trade the ARS at any time through July 2, 2012 without prior notice to us and must pay us par value for the ARS within one day of the sale transaction settlement. Additionally, UBS offered us a no net cost loan up to the market value of the ARS as determined by UBS until June 30, 2010 and we agreed to release UBS from certain potential claims related to the collateralized ARS in certain specified circumstances. During the three months ended December 31, 2008, we elected fair value accounting for the put option recorded in connection with the Rights Agreement. This election was made in order to mitigate volatility in earnings caused by accounting for the purchased put option and underlying ARS under different methods. The initial election of fair value led to a $3.3 million gain included in Other income, net for the put option asset, which is recorded in long-term trading securities.
34